



This is a repository copy of *SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease*.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/201360/>

Version: Published Version

---

**Article:**

Barnes, E. [orcid.org/0000-0002-0860-0831](https://orcid.org/0000-0002-0860-0831), Goodyear, C.S. [orcid.org/0000-0001-5926-5941](https://orcid.org/0000-0001-5926-5941), Willicombe, M. [orcid.org/0000-0002-6404-0584](https://orcid.org/0000-0002-6404-0584) et al. (154 more authors) (2023) SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease. *Nature Medicine*. ISSN 1078-8956

<https://doi.org/10.1038/s41591-023-02414-4>

---

**Reuse**

This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the authors for the original work. More information and the full terms of the licence here:

<https://creativecommons.org/licenses/>

**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.



[eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk)  
<https://eprints.whiterose.ac.uk/>

# SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease

---

Received: 5 August 2022

---

Accepted: 23 May 2023

---

Published online: 06 July 2023

---

 Check for updates

---

---

A list of authors and their affiliations appears at the end of the paper

---

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immune responses and infection outcomes were evaluated in 2,686 patients with varying immune-suppressive disease states after administration of two Coronavirus Disease 2019 (COVID-19) vaccines. Overall, 255 of 2,204 (12%) patients failed to develop anti-spike antibodies, with an additional 600 of 2,204 (27%) patients generating low levels ( $<380$  AU ml<sup>-1</sup>). Vaccine failure rates were highest in ANCA-associated vasculitis on rituximab (21/29, 72%), hemodialysis on immunosuppressive therapy (6/30, 20%) and solid organ transplant recipients (20/81, 25% and 141/458, 31%). SARS-CoV-2-specific T cell responses were detected in 513 of 580 (88%) patients, with lower T cell magnitude or proportion in hemodialysis, allogeneic hematopoietic stem cell transplantation and liver transplant recipients (versus healthy controls). Humoral responses against Omicron (BA.1) were reduced, although cross-reactive T cell responses were sustained in all participants for whom these data were available. BNT162b2 was associated with higher antibody but lower cellular responses compared to ChAdOx1 nCoV-19 vaccination. We report 474 SARS-CoV-2 infection episodes, including 48 individuals with hospitalization or death from COVID-19. Decreased magnitude of both the serological and the T cell response was associated with severe COVID-19. Overall, we identified clinical phenotypes that may benefit from targeted COVID-19 therapeutic strategies.

The rapid development of vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has been hugely effective in the management of the Coronavirus Disease 2019 (COVID-19) pandemic<sup>1,2</sup>. National vaccination programs have shown that COVID-19 vaccines prevent wild-type SARS-CoV-2 infection and protect against severe disease from other SARS-CoV-2 variants, including Omicron<sup>3</sup>. However, volunteers in the original vaccine trials were healthy, without known chronic disease and not receiving immune-modifying treatments. In the United Kingdom (UK), in 2019, more than 60% of people aged over 65 years had one or more chronic disease, with more than 12 million people aged 18–65 years living with a chronic condition

lasting more than 12 months<sup>4</sup>. UK government estimates suggest that 500,000 people have immune-suppressive diseases. Disease cohort studies<sup>5</sup> and population studies using primary care health records<sup>6</sup> showed that immune-suppressed patients are at increased risk of severe COVID-19 and death after SARS-CoV-2 infection in the pre-COVID-19 vaccine era. Many studies have shown suboptimal COVID-19 vaccine immune responses in cohorts of patients with chronic disease and in those receiving immune-suppressive therapy<sup>7–23</sup>. In general, these studies have focused on specific disease cohorts, and few have robustly evaluated cellular immune responses. Furthermore, vaccine responses against SARS-CoV-2 Omicron have been rarely assessed in specific

---

✉ e-mail: [Iain.McInnes@glasgow.ac.uk](mailto:Iain.McInnes@glasgow.ac.uk)

**Table 1 | Patient characteristics presented for patients in the deep immunophenotyping and serology groups**

	HC (236)	SC (112)	HM (33)	AAV (35)	IA (707)	HD (211)	HD on IS (36)	K-Tr (743)	L-Tr (83)	L-AI (73)	L-Cir (126)	CD (170)	UC (115)	IBD-U (5)	Auto-HSCT (43)	Allo-HSCT (145)	CAR-T (8)	Total (2,881)	
<b>Sex</b>																			
Male	104 (44%)	9 (8%)	21 (64%)	19 (54%)	236 (33%)	119 (56%)	20 (56%)	474 (64%)	52 (63%)	24 (33%)	68 (54%)	97 (57%)	70 (61%)	3 (60%)	26 (60%)	83 (57%)	5 (63%)	1430 (50%)	
Female	132 (56%)	103 (92%)	12 (36%)	16 (46%)	470 (66%)	92 (44%)	16 (44%)	269 (36%)	31 (37%)	49 (67%)	58 (46%)	73 (43%)	45 (39%)	2 (40%)	17 (40%)	62 (43%)	3 (38%)	1450 (50%)	
Unknown	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0%)	
<b>Age (years)</b>																			
15-44	22 (9%)	24 (21%)	2 (6%)	10 (29%)	130 (18%)	18 (9%)	5 (14%)	153 (21%)	17 (20%)	10 (14%)	8 (6%)	113 (66%)	69 (60%)	5 (100%)	4 (9%)	42 (29%)	4 (50%)	636 (22%)	
45-64	63 (27%)	55 (49%)	19 (58%)	17 (49%)	393 (56%)	61 (29%)	19 (53%)	361 (49%)	39 (47%)	39 (53%)	65 (52%)	54 (32%)	38 (33%)	0 (0%)	22 (51%)	72 (50%)	4 (50%)	1321 (46%)	
65-74	101 (43%)	24 (21%)	9 (27%)	4 (11%)	152 (21%)	58 (27%)	9 (25%)	172 (23%)	23 (28%)	19 (26%)	45 (36%)	3 (2%)	6 (5%)	0 (0%)	16 (37%)	30 (21%)	0 (0%)	671 (23%)	
75+	50 (21%)	9 (8%)	3 (9%)	4 (11%)	32 (5%)	73 (35%)	3 (8%)	57 (8%)	4 (5%)	5 (7%)	8 (6%)	0 (0%)	2 (2%)	0 (0%)	1 (2%)	1 (1%)	0 (0%)	252 (9%)	
Unknown	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0%)	
<b>Ethnicity</b>																			
White	193 (82%)	84 (75%)	26 (79%)	28 (80%)	625 (88%)	50 (24%)	14 (39%)	319 (43%)	76 (92%)	61 (84%)	116 (92%)	159 (94%)	104 (90%)	5 (100%)	40 (93%)	131 (90%)	7 (88%)	2038 (71%)	
Black	11 (5%)	7 (6%)	2 (6%)	0 (0%)	4 (1%)	54 (26%)	6 (17%)	59 (8%)	2 (2%)	0 (0%)	1 (1%)	1 (1%)	1 (1%)	0 (0%)	1 (2%)	1 (1%)	0 (0%)	150 (5%)	
Asian	16 (7%)	1 (1%)	2 (6%)	1 (3%)	10 (1%)	96 (45%)	14 (39%)	308 (41%)	1 (1%)	10 (14%)	4 (3%)	7 (4%)	5 (4%)	0 (0%)	1 (2%)	2 (1%)	1 (13%)	479 (17%)	
Mixed/ Other	12 (5%)	17 (15%)	1 (3%)	2 (6%)	20 (3%)	9 (4%)	1 (3%)	36 (5%)	3 (4%)	2 (3%)	3 (2%)	3 (2%)	3 (3%)	0 (0%)	0 (0%)	4 (3%)	0 (0%)	116 (4%)	
Not known	4 (2%)	3 (3%)	2 (6%)	4 (11%)	48 (7%)	2 (1%)	1 (3%)	21 (3%)	1 (1%)	0 (0%)	2 (2%)	0 (0%)	2 (2%)	0 (0%)	1 (2%)	7 (5%)	0 (0%)	98 (3%)	
<b>BMI</b>																			
Under-weight	1 (0%)	1 (1%)	0 (0%)	0 (0%)	10 (1%)	8 (4%)	1 (3%)	3 (0%)	0 (0%)	3 (4%)	0 (0%)	6 (4%)	4 (3%)	0 (0%)	0 (0%)	6 (4%)	1 (13%)	44 (2%)	
Healthy weight	14 (6%)	31 (28%)	11 (33%)	7 (20%)	163 (23%)	35 (17%)	4 (11%)	62 (8%)	30 (36%)	24 (33%)	25 (20%)	92 (54%)	54 (47%)	5 (100%)	15 (35%)	57 (39%)	2 (25%)	631 (22%)	
Overweight	7 (3%)	20 (18%)	10 (30%)	8 (23%)	261 (37%)	32 (15%)	4 (11%)	81 (11%)	26 (31%)	28 (38%)	34 (27%)	39 (23%)	39 (34%)	0 (0%)	14 (33%)	42 (29%)	4 (50%)	649 (23%)	
Obese	1 (0%)	28 (25%)	10 (30%)	15 (43%)	257 (36%)	42 (20%)	4 (11%)	71 (10%)	26 (31%)	14 (19%)	60 (48%)	28 (16%)	14 (12%)	0 (0%)	10 (23%)	20 (14%)	0 (0%)	600 (21%)	
Unknown	5 (2%)	32 (29%)	2 (6%)	5 (14%)	16 (2%)	94 (45%)	23 (64%)	526 (71%)	1 (1%)	4 (5%)	7 (6%)	5 (3%)	4 (3%)	0 (0%)	4 (9%)	20 (14%)	1 (13%)	749 (26%)	
Data unavailable	208 (88%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	208 (7%)	
<b>Prior COVID</b>																			
No confirmed infection	198 (84%)	95 (85%)	30 (91%)	33 (94%)	637 (90%)	106 (50%)	23 (64%)	692 (93%)	76 (92%)	69 (95%)	111 (88%)	154 (91%)	101 (88%)	5 (100%)	36 (84%)	112 (77%)	5 (63%)	2483 (86%)	
Yes	38 (16%)	17 (15%)	3 (9%)	2 (6%)	70 (10%)	105 (50%)	13 (36%)	51 (7%)	7 (8%)	4 (5%)	15 (12%)	16 (9%)	14 (12%)	0 (0%)	7 (16%)	33 (23%)	3 (38%)	398 (14%)	
<b>Vaccine type</b>																			
ChAdOx nCoV-19	156 (66%)	44 (39%)	19 (58%)	33 (94%)	591 (84%)	127 (60%)	29 (81%)	326 (44%)	62 (75%)	52 (71%)	93 (74%)	140 (82%)	99 (86%)	3 (60%)	37 (86%)	61 (42%)	4 (50%)	1876 (65%)	
BNT162b2	80 (34%)	61 (54%)	13 (39%)	2 (6%)	116 (16%)	84 (40%)	7 (19%)	410 (55%)	21 (25%)	21 (29%)	33 (26%)	30 (18%)	16 (14%)	2 (40%)	5 (12%)	70 (48%)	4 (50%)	975 (34%)	
mRNA1273	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	2 (1%)	0 (0%)	3 (0%)	
Unknown	0 (0%)	6 (5%)	1 (3%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	7 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (2%)	12 (8%)	0 (0%)	27 (1%)	
<b>Smoking status</b>																			
Never smoked	20 (8%)	26 (23%)	14 (42%)	15 (43%)	369 (52%)	41 (19%)	7 (19%)	163 (22%)	45 (54%)	34 (47%)	40 (32%)	96 (56%)	69 (60%)	4 (80%)	7 (16%)	47 (32%)	6 (75%)	1003 (35%)	
Previous smoker	1 (0%)	18 (16%)	2 (6%)	8 (23%)	255 (36%)	17 (8%)	2 (6%)	37 (5%)	28 (34%)	25 (34%)	55 (44%)	49 (29%)	30 (26%)	0 (0%)	4 (9%)	27 (19%)	1 (13%)	559 (19%)	
Current smoker	0 (0%)	7 (6%)	0 (0%)	4 (11%)	72 (10%)	12 (6%)	0 (0%)	10 (1%)	2 (2%)	10 (14%)	23 (18%)	23 (14%)	13 (11%)	1 (20%)	0 (0%)	4 (3%)	0 (0%)	181 (6%)	

**Table 1 (continued) | Patient characteristics presented for patients in the deep immunophenotyping and serology groups**

	HC (236)	SC (112)	HM (33)	AAV (35)	IA (707)	HD (211)	HD on IS (36)	K-Tr (743)	L-Tr (63)	L-AI (73)	L-Cir (126)	CD (170)	UC (115)	IBD-U (5)	Auto-HSCT (43)	Allo-HSCT (145)	CAR-T (8)	Total (2,881)
Unknown	7 (3%)	61 (54%)	17 (52%)	8 (23%)	11 (2%)	141 (67%)	27 (75%)	533 (72%)	8 (10%)	4 (5%)	8 (6%)	2 (1%)	3 (3%)	0 (0%)	32 (74%)	67 (46%)	1 (13%)	930 (32%)
Data unavailable	208 (88%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	208 (7%)
<b>Diabetes</b>																		
No	24 (10%)	101 (90%)	31 (94%)	27 (77%)	641 (91%)	107 (51%)	22 (61%)	473 (64%)	66 (80%)	59 (81%)	71 (56%)	165 (97%)	113 (98%)	5 (100%)	37 (86%)	138 (95%)	8 (100%)	2,088 (72%)
Yes	0 (0%)	6 (5%)	2 (6%)	7 (20%)	62 (9%)	104 (49%)	14 (39%)	269 (36%)	17 (20%)	14 (19%)	55 (44%)	5 (3%)	2 (2%)	0 (0%)	4 (9%)	6 (4%)	0 (0%)	567 (20%)
Not known	4 (2%)	5 (4%)	0 (0%)	1 (3%)	4 (1%)	0 (0%)	0 (0%)	1 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	2 (5%)	1 (1%)	0 (0%)	18 (1%)
Data unavailable	208 (88%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	208 (7%)

Reported as n(%). ANCA-associated vasculitis; CD, Crohn's disease; HC, healthy controls; HD, hemodialysis; HD on IS, hemodialysis on immunosuppression; HM, hematological malignancy; IA, inflammatory arthritis; IBD-U, undefined inflammatory bowel disease; K-Tr, kidney transplant; L-AI, autoimmune hepatitis; L-Cir, liver cirrhosis; L-Tr, liver transplant; SC, solid cancer; UC, ulcerative colitis.

patient cohorts<sup>24,25</sup>. Population studies including immune-suppressed patients have shown lower rates of SARS-CoV-2 spike antibody positivity after vaccination with only moderate vaccine effectiveness<sup>26</sup> and have identified immune-suppressive disease after vaccination as a risk factor for severe COVID-19 and death<sup>27,28</sup>. Immune-suppressive disease remains a risk factor for severe outcomes with Omicron infection<sup>29-31</sup>, even though this variant appears less pathogenic, even when accounting for confounders, including vaccination status<sup>32</sup>.

In this prospective, multi-center study (Observational Cohort trial T cells, Antibodies and Vaccine Efficacy in SARS-CoV-2 (OCTAVE)), we evaluated functional humoral and T cell responses after COVID-19 vaccination, using centralized immune assays in patients receiving immune-suppressive therapy (for solid cancer, hematological malignancy, ANCA-associated vasculitis on rituximab, inflammatory arthritis, liver and kidney transplantation, autoimmune liver disease on immunosuppression, inflammatory bowel disease, ulcerative colitis and undefined inflammatory bowel disease); patients receiving autologous and allogeneic hematopoietic stem cell transplant (auto-HSCT and allo-HSCT); patients treated with chimeric antigen receptor (CAR) T cells; or patients with disease states known to modulate immune responses intrinsically (patients with end-stage kidney disease receiving hemodialysis with or without immune suppression and patients with advanced liver disease). Patients were vaccinated using mRNA (BNT162b2 or mRNA-1273) or ChAdOx1 nCoV-19 encoding ancestral SARS-CoV-2 spike antigens according to UK government-recommended vaccine schedules, and vaccine responses were evaluated before and after homologous first dose (V1) and second dose (V2) vaccination.

Patients were recruited for evaluation of SARS-CoV-2 serological responses 28 d after V2 with the magnitude of the T cell response assessed in a large subset of patients longitudinally (primary study endpoints). These responses were compared to a healthy control cohort matched by age, sex, prior SARS-CoV-2 infection and vaccine type, and the safety profile of vaccines in patient populations was assessed. Cellular and humoral responses were associated with SARS-CoV-2 infection events and COVID-19 disease severity. Exploratory endpoints included characterization of functional T cell and humoral responses and immune analysis in blood and saliva against variants of concern (VOCs). Using pairwise and regression analysis, we determined the contribution of disease phenotype, drug therapy and vaccine type to COVID-19 humoral and cellular vaccine responses, identifying patient subgroups that failed to seroconvert. Using uniform sampling timepoints and centralized immune assays, we directly compared COVID-19 vaccine immune responsiveness and infection outcomes among multiple disease phenotypes in immune-suppressive disease.

## Results

### Patient Demographics

OCTAVE recruited 2,686 patients, including 2,012 for the evaluation of SARS-CoV-2 anti-receptor-binding domain (RBD) antibody responses (serology cohort) 28 d after V2 and 674 into a deep immunophenotyping cohort for the evaluation of T cell and humoral responses over time (Extended Data Fig. 1). In addition, 236 matched healthy control individuals (UK Health Security Agency (UKHSA) CONSENSUS and PITCH cohorts) were available for comparative analysis. Demographic data (available in 2,645 patients and 236 healthy controls) (Table 1) show that 1,430 of 2,881 (50%) patients were male, although distribution varied by disease cohort. Most patients, 2,629 of 2,881 (91%), were younger than 75 years of age; 2,038 of 2,881 (70%) reported White ethnicity; 479 of 2,881 (17%) reported Asian ethnicity; and 150 of 2,881 (5%) reported Black ethnicity. Previous SARS-CoV-2 infection (SARS-CoV-2 polymerase chain reaction (PCR) positive or anti-nucleocapsid or anti-spike antibody detected at baseline) was reported in 398 of 2,881 (14%) individuals, with higher rates in some disease cohorts (for example, hemodialysis in 104/211 (49%)). Of 2,881 participants (44%), 1,249 had overweight or obesity, and 567 (20%) had type 1 or type 2 diabetes.



Of 2,881 participants, 1,876 (65%) received ChAdOx1 nCoV-19, and 975 (34%) received BNT162b2. Three participants received mRNA-1273 (in 27 individuals, the vaccine type was unknown).

### COVID-19 serology after two vaccines

Immunogenicity after two COVID-19 vaccines was evaluable in 2,204 patients and 225 matched healthy controls (Table 1). We assessed the rate of seropositivity (anti-RBD antibody titer  $\geq 0.8$  AU ml<sup>-1</sup>) after V2 (Fig. 1a): in healthy controls, 222 of 225 (99%) were seropositive compared to 1,949 of 2,204 (88%) patients (Fisher's exact test,  $P < 0.001$ ) (Fig. 1a and Supplementary Table 1). Compared to the healthy control group, there was a decrease in rates of seropositivity in ANCA-associated vasculitis (8/29, 28%), hemodialysis on immunosuppression (24/30, 80%), kidney transplant (317/458, 69%), liver transplant (61/81, 75%), auto-HSCT (28/33, 85%), allo-HSCT (83/96, 86%) and CAR-T (4/8, 50%) disease groups ( $P < 0.003$ , Bonferroni-adjusted alpha) (Fig. 1a and Supplementary Table 1). All other groups had a similar rate of seropositivity to healthy controls (cirrhosis, Crohn's disease and ulcerative colitis, 100% seropositive rate).

Compared to the healthy control group, the median anti-RBD titers after V2 were decreased in the ANCA-associated vasculitis ( $z = 8.42$ ,  $P < 0.001$ ), inflammatory arthritis ( $z = 4.92$ ,  $P < 0.001$ ), kidney transplant ( $z = 10.58$ ,  $P < 0.001$ ), liver transplant ( $z = 6.82$ ,  $P < 0.001$ ), Crohn's disease ( $z = 4.32$ ,  $P = 0.001$ ) and allo-HSCT ( $z = 4.18$ ,  $P = 0.002$ ) cohorts; other disease groups with enough participants to be included in the analysis did not differ from the healthy control group (Fig. 1b and Supplementary Table 2).

Low serological response threshold was defined by assessing anti-RBD Ig responses in healthy controls and identifying the upper value of the lowest decile ( $< 380$  AU ml<sup>-1</sup>) (Fig. 1b). There was a greater number of low responders across the entire disease cohort compared to the healthy control group (Fig. 1a). Combining no-responders and low-responders, there were significantly more patients in ANCA-associated vasculitis (Fisher's exact  $P < 0.001$ ), inflammatory arthritis ( $\chi^2 = 24.48$ ,  $P < 0.001$ ), hemodialysis on immunosuppression ( $\chi^2 = 12.14$ ,  $P < 0.001$ ), kidney transplant ( $\chi^2 = 120.03$ ,  $P < 0.001$ ), liver transplant ( $\chi^2 = 51.70$ ,  $P < 0.001$ ), autoimmune liver disease ( $\chi^2 = 14.69$ ,  $P < 0.001$ ), Crohn's disease ( $\chi^2 = 20.02$ ,  $P < 0.001$ ) and allo-HSCT ( $\chi^2 = 30.81$ ,  $P < 0.001$ ) groups compared to the healthy control group (Fig. 1b and Supplementary Table 3).

We examined the effect of prior SARS-CoV-2 infection on anti-RBD Ig titers after V2 in the healthy control and disease groups (Fig. 1c and Supplementary Table 4). In those previously infected, anti-RBD Ig titers were significantly increased in healthy controls ( $P < 0.0001$ ) and in the total OCTAVE cohort ( $P < 0.0001$ ). Within disease groups, patients with previous infection and inflammatory arthritis ( $P < 0.0001$ ), hemodialysis ( $P < 0.0001$ ), hemodialysis on immunosuppression ( $P = 0.0002$ ), kidney transplant ( $P < 0.0001$ ), Crohn's disease ( $P = 0.0006$ ), ulcerative colitis ( $P = 0.0014$ ) or auto-HSCT ( $P = 0.0004$ ) had higher titers than SARS-CoV-2-naïve patients (Supplementary Table 4).

Median anti-RBD Ig titer was significantly higher in patients who received two doses of BNT162b2 ( $n = 695$ ) compared to two doses of

ChAdOx1 nCoV-19 ( $n = 1,497$ ) ( $P < 0.0001$ ) and within the solid cancer ( $P = 0.0004$ ), inflammatory arthritis ( $P < 0.0001$ ), kidney transplant ( $P < 0.0001$ ), autoimmune liver disease ( $P < 0.0001$ ) and cirrhosis ( $P < 0.0001$ ) individual disease groups (Fig. 1d and Supplementary Table 5). This was also seen in the healthy control group.

### SARS-CoV-2 spike and common cold coronavirus immunoglobulins

Serological and cellular immune responses were evaluated before V1, immediately before V2 and 28 d after V2 in 674 patients and in healthy controls matched by age, sex, prior SARS-CoV-2 and vaccine type (Supplementary Table 6). Median anti-RBD Ig titers were lower before V2 in ANCA-associated vasculitis, hemodialysis on immunosuppression, liver transplant, allo-HSCT and CAR-T groups compared to healthy controls (Fig. 2a and Supplementary Table 7) but increased after a second COVID-19 vaccine in all disease groups other than ANCA-associated vasculitis. Spike, RBD and N-terminal domain (NTD) IgG and spike IgA responses significantly increased after both one vaccine dose ( $P < 0.0001$ ) and two vaccine doses (IgG  $P < 0.0001$  and IgA  $P = 0.0003$ ). Spike IgM and NTD IgA increased significantly only after the first dose (Fig. 2b). IgM responses to RBD and NTD did not increase after either dose (Extended Data Fig. 2a,b). We correlated IgG/IgA/IgM to each common cold coronavirus (CCC) spike protein at baseline with SARS-CoV-2 spike IgG after one and two vaccines in seronegative anti-nucleocapsid IgG patients: only IgG to HCoV-OC43 showed a weak positive correlation after the first vaccine (Fig. 2c and Extended Data Fig. 3).

### Serological responses to SARS-CoV-2 VoC in blood and saliva

We assessed the cross-reactivity of SARS-CoV-2 spike ancestral antibody responses to VOCs (Alpha (B.1.1.7), Beta (B.1.351), Gamma (P.1), Delta (B.1.617.2) and Omicron (B.1.1.529 and BA.1)) in 59 patients from the liver transplant, autoimmune liver disease, cirrhosis and inflammatory arthritis cohorts, representing a range of low to high anti-RBD Ig titers (Roche assay, range: 257–29,332 AU ml<sup>-1</sup>) after V2. Compared to ancestral, median spike IgG and spike-ACE2 binding was significantly decreased to all VOCs except Alpha in all disease groups but most notably to Omicron BA.1 (Fig. 2d,e). Binding to ancestral and each VOC spike correlated with post-V2 anti-RBD antibody titer (Extended Data Fig. 4). Salivary Ig inhibited ancestral spike ACE2 binding with 80% efficiency (Fig. 2f) but was reduced against all VOCs. Inhibition of ACE2 binding in saliva and serum did not correlate (Extended Data Fig. 5). In live microneutralization assays, all patients neutralized ancestral SARS-CoV-2 (mean half-maximal inhibitory concentration (IC<sub>50</sub>) = 589), but there was a 13-fold decrease in the neutralization Omicron BA.1 (mean IC<sub>50</sub> = 44). Only 27% of patients could neutralize Omicron BA.1 (Fig. 2g,h). There was a significant positive correlation between anti-RBD Ig titers and ancestral and Omicron BA.1 neutralization (Fig. 2g). Notably, those with a Roche anti-RBD Ig titer of  $< 4,000$  AU ml<sup>-1</sup> were largely unable to neutralize Omicron. Patients with previous SARS-CoV-2 infection had significantly higher microneutralization IC<sub>50</sub> than naïve patients (Fig. 2h), with a higher proportion able to neutralize Omicron (9/11 versus 7/48,  $P < 0.0001$ , Fisher's exact test).





**Fig. 1 | Anti-SARS-CoV-2 RBD total Ig responses in whole OCTAVE cohort at post-V2 timepoint.** **a**, Proportion of group 1 and group 2 non ( $< 0.8$  AU ml<sup>-1</sup>), low ( $< 380$  AU ml<sup>-1</sup>) and high ( $> 380$  AU ml<sup>-1</sup>) anti-SARS-CoV-2 spike RBD total Ig responses. Statistical comparisons of the proportion of low and no versus high response and no versus low and high response in disease groups compared to healthy controls are presented. **b**, Magnitude of serological response in disease groups and healthy controls. Statistical comparisons comparing disease group to healthy controls are presented. **c**, Anti-SARS-CoV-2 spike RBD total Ig responses comparing previously infected with infection-naïve patients. Statistical comparison of infection-naïve individuals and previously infected individuals within each group is presented. **d**, Anti-SARS-CoV-2 spike RBD total Ig responses separated by vaccine type. Statistical comparison of vaccine type

in each disease group is presented. Unpaired statistical comparison was made on all groups using a two-sided Kruskal–Wallis with post hoc Dunn's testing. Comparisons of proportions were performed using  $\chi^2$  or Fisher's exact tests adjusted for significance using Bonferroni correction (adjusted alpha = 0.003). Only significant comparisons are presented. \* indicates statistically significant by Bonferroni-adjusted alpha. Boxes represent median and IQR; whiskers represent  $\pm 1.5 \times$  IQR. AAV, ANCA-associated vasculitis; CD, Crohn's disease; HC, healthy controls; HD, hemodialysis; HD on IS, hemodialysis on immunosuppression; HM, hemotological malignancy; IA, inflammatory arthritis; L-AI, autoimmune hepatitis; L-Cir, liver cirrhosis; L-Tr, liver transplant; SC, solid cancer; UC, ulcerative colitis.

**Cellular immune responses after vaccination**

T cell responses to spike and nucleocapsid were evaluated before V1, before V2 and 28 d after V2 using the Oxford Immunotec T-SPOT

Discovery IFN $\gamma$  ELISpot assay in 656 patients and 210 matched healthy controls. After V2, the hemodialysis ( $P < 0.003$ ) and allo-HSCT ( $P < 0.003$ ) groups had a significantly higher proportion of T cell



non-response compared to the healthy control group (Fig. 3a and Supplementary Table 8). IFN $\gamma$ -secreting T cell magnitude to spike antigens was lower in liver transplant ( $z = 3.821, P = 0.004$ ) and allo-HSCT ( $z = 3.339, P = 0.03$ ) groups compared to the healthy control group (Fig. 3b and Supplementary Table 9). To complement the serological characterization of Omicron BA.1 responses, an in-house IFN $\gamma$  ELISpot assay was used to investigate T cell responses to ancestral and Omicron BA.1 spike in the 59-patient subset after V2. Regardless of prior SARS-CoV-2 status, the T cell response to full spike was maintained against Omicron peptides relative to ancestral (Fig. 3c,d), although stimulation with a reduced peptide set containing only peptides with variant amino acids relative to ancestral showed a significant decrease in Omicron reactivity (Fig. 3c). Serological and T cell responses showed weak correlations at pre-V2 only in healthy controls ( $r = 0.24, P = 0.02$ ) but at pre-V2 and post-V2 timepoints in the overall patient cohort (pre-V1:  $r = 0.34, P < 0.0001$ ; post-V2:  $r = 0.22, P < 0.0001$ ) (Fig. 3e,f and Extended Data Fig. 6). In the ANCA-associated vasculitis group (with all patients taking B-cell-depleting therapies), there was no relationship between anti-RBD Ig and SARS-CoV-2 spike T cell responses; here, antibody responses were low after both vaccines, but many generated robust T cell responses after one vaccine (Fig. 3g,h). Positive correlations were also seen in disease subgroups at pre-V2 and/or post-V2 timepoints (Extended Data Fig. 6).

### Predictors of vaccine humoral and cellular responses

The contribution of demographics, disease group, vaccine type, prior SARS-CoV-2, therapeutic regimen and time between vaccines to vaccine immunogenicity was assessed using multivariable logistic regression in OCTAVE patients compared to matched healthy controls. Patients aged 65–74 years had significantly lower odds of having a robust serological response (Roche anti-RBD Ig > 380 AU ml $^{-1}$ ) compared to patients in the 15–44-year agegroup (Fig. 4a and Supplementary Table 10). Patients of Asian versus White ethnicity had significantly higher odds of having a robust serological response (odds ratio (OR): 1.43, 95% confidence interval (CI) 1.02–2.01). Disease groups more likely to have a low or absent serological response (compared to the healthy control group) included ANCA-associated vasculitis (OR: 0.03, 95% CI 0.01–0.13), inflammatory arthritis (OR: 0.45, 95% CI 0.27–0.77), hemodialysis (OR: 0.29, 95% CI 0.16–0.51), kidney transplant (OR: 0.26, 95% CI 0.12–0.57), Crohn's disease (OR: 0.42, 95% CI 0.23–0.76), allo-HSCT (OR: 0.25, 95% CI 0.14–0.46) and CAR-T (OR: 0.03, 95% CI 0–0.2). Patients receiving anti-metabolites (OR: 0.32, 95% CI 0.22–0.47), calcineurin inhibitors (OR: 0.43, 95% CI 0.23–0.83) and corticosteroids (OR: 0.64, 95% CI 0.47–0.88) were each more likely to have a low or absent serological response compared to healthy controls. Prior SARS-CoV-2 infection (OR: 9.48, 95% CI 6–14.97) and vaccination with BNT162b2 vaccine (OR: 2.99, 95% CI 2.33–3.84) significantly increased the odds of having a high serological response. These findings were generally recapitulated when analyzing the OR of likelihood of anti-RBD Ig seropositivity (>0.8 AU ml $^{-1}$ ) (Extended Data

Fig. 7 and Supplementary Table 11), although liver transplant (OR: 0.14, 95% CI 0.03–0.63) and hemodialysis on immunosuppression (OR: 0.08, 95% CI 0.02–0.42) disease groups were additionally associated with a decreased rate of seropositivity compared to the healthy control group.

In evaluating T cell responses, we used a responder threshold of  $\geq 4$  spot-forming cells (SFCs) per 10 $^6$  peripheral blood mononuclear cell (PBMCs) (Fig. 4b and Supplementary Table 12). The only disease group with reduced cellular responses was allo-HSCT (OR: 0.09, 95% CI 0.02–0.41). In contrast to the serological results, vaccination with BNT162b2 was associated with significantly decreased odds of generating a cellular response (OR: 0.23, 95% CI 0.11–0.51). Previous SARS-CoV-2 infection significantly increased the odds of generating a cellular response (OR: 4.05, 95% CI 1.5–10.9). No other variables were associated with T cell response.

### SARS-CoV-2 infection and COVID-19 severity

SARS-CoV-2 infection outcomes were collected in patients with both serology and infection data (V2 to 6 months after V2 in 1,648 patients and 6 months after V2 to 12 months after V1 in 1,617 patients). Overall, 474 infections were reported (Supplementary Table 13), including one infection that occurred during the Alpha VOC time epoch (14 January 2021–24 May 2021), 110 Delta (24 May 2021–20 December 2021), 336 Omicron (20 December 2021–17 October 2022) and 27 with exact infection date unknown. In total, 113 of 474 (24%) infections occurred within 6 months of V2, and 361 of 474 (76%) infections occurred at the >6-month timepoint. Most infections occurred in patients with kidney transplant, inflammatory arthritis and Crohn's disease, with infection rates of 123/456 (27.0%), 79/689 (11.5%) and 67/156 (42.9%), respectively. Four hundred thirty-one infections were in patients who were previously infection naive (Supplementary Table 14), and 43 patients were previously SARS-CoV-2 infected. There was a higher rate of infection (infections per 1,000 d after V2) in patients with absent serological or T cell responses compared to those with high responses (Fig. 5a,b). However, most patients in OCTAVE overall had high serology (61.2%) and measurable T cell responses (88.5%), and most infections occurred in these groups (Fig. 5c–e and Supplementary Table 13).

Infection severity was evaluated in 440 of 474 (92.8%) infections. Most infections of known severity were mild (397/440, 90.2%), including asymptomatic infection (49/440, 11.1%) and symptomatic infection that did not require hospitalization (348/440, 79.1%) (Fig. 5c,d and Extended Data Table 1). Severe disease requiring hospitalization or COVID-19-related death was reported in 43 of 440 (9.8%) infections; 15 of 440 (3.4%) patients required oxygen; three patients were admitted to the intensive treatment unit (ITU) (0.7%); and 10 of 440 patients died (2.3%). Five patients died of COVID-19 without serological titers taken and were excluded from subsequent analysis. Infections occurring within 6 months after V2 (11/107 (10.2%)) were not more severe (hospitalized or died) than those at more than 6 months after V2 (32/333 (9.6%)) (Fig. 5c,d). Of 434 patients with known severity and precise date

### Fig. 2 | Serological responses to CCCs and SARS-CoV-2 VOCs after vaccination.


**a**, Anti-SARS-CoV-2 RBD-binding total Ig before first vaccine (pre-V1) and before (pre-V2) and after (post-V2) second vaccine in group 1 participants. **b**, Anti-SARS-CoV-2 spike binding IgG, IgM and IgA assessed at all available timepoints. IgG was assessed in all group 1 participants; IgM and IgA were assessed in group 1 participants in the UC, CD, L-Tr, L-AI, L-Cir, IA and ANCA-associated vasculitis disease groups. Lines indicate threshold for seropositivity. **c**, Spearman's correlation of anti-HCoV-OC43 spike IgG at pre-V1 compared to pre-V2 anti-SARS-CoV-2 full-spike IgG assessed in all group 1 participants. **d**, Serum IgG binding to SARS-CoV-2 VOC spike at post-V2 timepoint. **e, f**, Inhibition of SARS-CoV-2 VOC spike binding to hACE2 by participant serum (**e**) or saliva (**f**) at post-V2 timepoint. **g, h**, Microneutralization of live ancestral or omicron BA.1 SARS-CoV-2 at the post-V2 timepoint (**h**). Correlation of microneutralization IC $_{50}$  with ancestral anti-SARS-CoV-2 RBD-binding total Ig (**g**) and microneutralization IC $_{50}$  separated by previous SARS-CoV-2 infection status. **d, e, g, h**,  $n = 59$  participants selected from

liver and inflammatory disease groups with anti-SARS-CoV-2 RBD total Ig above 250 AU ml $^{-1}$ . **f**,  $n = 168$  participants selected from inflammatory and liver disease groups. **d–f**, Lines represent median and IQR. Paired statistical comparisons among multiple groups (**d–f, h**) were assessed using two-sided Friedman's test with Dunn's correction or Wilcoxon's rank-sum test with Bonferroni correction. Unpaired statistical comparisons among multiple groups were assessed using two-sided Mann–Whitney  $U$ -test with Bonferroni correction. \* $P < 0.05$ , \*\* $P < 0.01$ , \*\*\* $P < 0.001$ , \*\*\*\* $P < 0.0001$ . AAV, ANCA-associated vasculitis; CD, Crohn's disease; HC, healthy controls; HD, hemodialysis; HD on IS, hemodialysis on immunosuppression; HM, hematological malignancy; IA, inflammatory arthritis; L-AI, autoimmune hepatitis; L-Cir, liver cirrhosis; L-Tr, liver transplant; MNA, microneutralization; Nucleocapsid negative, N-ve; Nucleocapsid positive, N+ve; NS, not significant; SC, solid cancer; V1, COVID-19 vaccine dose 1; V2, COVID-19 vaccine dose 2; UC, ulcerative colitis.



of infection, more severe infections occurred in those infected in the Delta versus the Omicron time epochs (eight died and 23 severe/107 Delta versus two died and 17 severe/327 Omicron;  $P < 0.0001$ ). Severe

disease occurred predominantly in patients with renal disease (hemodialysis 5/43 (11.6%), hemodialysis on immunosuppression 2/9 (22%) and kidney transplant 23/118 (19.5%)) (Extended Data Table 1).



In some disease groups, infection rates were low but the proportion of severe disease was notably high (AAV (1/3, 33%), auto-HSCT (1/2, 50%) and CAR-T (3/3, 100%)). Low rates of severe disease were reported in ulcerative colitis (0/42, 0%) and Crohn's disease (1/62, 1.6%). COVID-19-related deaths occurred in ANCA-associated vasculitis, hemodialysis, hemodialysis on immunosuppression, kidney transplant, auto-HSCT and CAR-T groups.

Infection severity was increased in patients with no (20/61, 32.3% severe) or low (13/89, 14.6%) post-V2 serological response compared to those with high serological response (10/290, 3.4%) (no versus low and high,  $P < 0.0001$ ) (Fig. 5c,d), but post-V2 T cell responder status was not significantly associated with increased COVID-19 severity (4/18 (22.2%) non-response versus 7/80 (8.8%) response ( $P = 0.11$ , Fisher's exact test)) (Fig. 5e,f and Extended Data Table 2). Of the COVID-19-related deaths, eight of 10 individuals had no detectable or low post-V2 serological response, and two of four (50%) individuals had no detectable T cell response. The magnitude of post-V2 anti-SARS-CoV-2 RBD Ig and spike-specific T cells were each significantly reduced (Ig:  $P < 0.0001$ , T cell:  $P = 0.033$ ) in patients with severe COVID-19 compared to mild disease (Fig. 5g,h). These findings were generally recapitulated when patients infected at baseline were removed from analysis (Supplementary Tables 14–16).

### Adverse events

Adverse events (AEs) reported in 2,662 post-V1 and 2,629 post-V2 (Supplementary Tables 17 and 18) patients were generally mild (>97% of AEs after V1 and V2 were grade 1 or 2, with none higher than grade 3). Local injection site reactions were most common (27% post-V1 and 21% post-V2). Other common AEs included headache (16% post-V1 and 10% post-V2), chills (11% post-V1 and 4% post-V2), myalgia (10% post-V1 and 5% post-V2) and pyrexia/fever (10% post-V1 and 5% post-V2). Two serious adverse reactions (myalgia and cough) resulted in hospitalization but resolved without sequelae (Supplementary Table 19). One suspected unexpected serious adverse reaction (SUSAR) of thrombocytopenia was reported (Supplementary Table 20).

### Discussion

People with immune-suppressive disease remain vulnerable to COVID-19 (refs. 27,29–31), and identifying patient populations most at risk remains a UK government imperative. We show that, after two vaccines, in comparison to healthy volunteers, a substantial minority of immune-suppressed patients generated low-magnitude SARS-CoV-2 antibodies (in particular, ANCA-associated vasculitis on rituximab, hemodialysis on immunosuppressive therapy and solid organ transplant recipients), and that, although T cell responses were generally maintained, these were also reduced in some patient groups (hemodialysis, allo-HSCT and liver transplant recipients). Lower serological or T cell responses were associated with hospitalization or death from COVID-19.

Although vaccine correlates of immune protection against SARS-CoV-2 are not precisely defined, there is consensus that higher

antibody titers are advantageous<sup>33–38</sup>. Waning immunity enhances disease susceptibility, especially in patients with additional comorbidities<sup>39</sup>, whereas higher levels of antibodies generated by booster vaccines are protective<sup>40</sup>. SARS-CoV-2-specific T cells protect against SARS-CoV-2 infection<sup>41</sup> and appear less susceptible to viral escape as VOCs have emerged<sup>42</sup>. Previous studies highlighted the role of serological responses in protecting immune-suppressed patients, including (1) inflammatory arthritis with breakthrough infections increased in those who fail to seroconvert after vaccination<sup>43</sup>; (2) primary immune deficiency with increased COVID-19 mortality compared to the general population after vaccination<sup>44</sup>; and (3) renal disease with both breakthrough infection and COVID-19 severity/mortality correlating with serological responses<sup>44–46</sup>.

SARS-CoV-2 infection rates varied among disease subtypes and were higher in patients with no detectable antibody or T cells. However, infection rates cannot be confidently ascribed to disease phenotype, as social shielding behavior and SARS-CoV-2 exposure are likely to have differed among groups. However, disease severity in those infected can be definitively correlated with vaccine responsiveness. Although most (93.6%) patients had asymptomatic or mild infection, a substantial number had severe COVID-19 (33/440), and, additionally, 15 patients died. Patients with severe COVID-19 included ANCA-associated vasculitis, inflammatory arthritis, hemodialysis, hemodialysis on immunosuppression, kidney transplant, liver transplant, cirrhosis, Crohn's disease, allo/auto-HSCT and CAR-T. Failure to seroconvert and the magnitude of the serological and cellular response were each associated with severe disease. However, one quarter of patients with severe disease seroconverted and had antibody levels similar to healthy controls, highlighting the fact that other factors contribute to disease susceptibility—for example, disease phenotype and/or comorbidities. Although most infections occurred during the Omicron time epoch, there were proportionally many more severe infections in the Delta epoch. The Omicron epoch coincided with the rollout of new therapeutic strategies, additional vaccines and a dominant VOC that is less pathogenic<sup>32</sup>, and it is not possible to disentangle the relative contribution of each of these to clinical outcomes in our study.


Vaccination with BNT162b2 generated higher antibody responses, whereas cellular responses were higher in patients who received ChAdOx1 nCoV-19, as previously shown in healthy populations<sup>47–52</sup>. Two studies in hemodialysis and solid organ transplant recipients assessed cellular responses in different vaccine types and showed no difference, but responses were low magnitude and the studies were underpowered to detect a difference<sup>16,53</sup>. The reasons why ChAd vaccines generate higher T cell responses than mRNA vaccines may relate to more persistent antigen expression in lymph nodes and the stimulation of distinct immune pathways, with ChAdOx dependent on robust follicular helper T (T<sub>fh</sub>) cell responses<sup>54</sup>, whereas mRNA vaccines are T<sub>fh</sub> independent<sup>55</sup>. Heterologous vaccination most effectively boosts T cell and antibody titers in healthy people and in solid organ transplant recipients<sup>50,56,57</sup> and should be further evaluated in immune-suppressed patient groups. In this study, all immune-suppressant drug classes evaluated (other

**Fig. 3 | T cell responses to ancestral and Omicron BA.1 SARS-CoV-2 after vaccination. a, b**, IFN $\gamma$  T cell response to SARS-CoV-2 spike measured by Oxford Immunotec assay presented as the proportion of individuals with or without an anti-SARS-CoV-2 spike T cell response (**a**) and the magnitude of IFN $\gamma$  T cell response in disease groups ( $n = 645$ ) and healthy controls ( $n = 189$ ) (**b**). **a, b**, The statistical comparison presented is disease group compared to healthy controls (HC) in all participants in group 1. **c, d**, IFN $\gamma$  T cell response to ancestral and Omicron BA.1 spike or pools of peptides covering regions mutated in BA.1 and their ancestral equivalents, measured by in-house IFN $\gamma$  ELISpot at post-V2 timepoint ( $n = 59$  participants selected from liver, rheumatic and inflammatory disease cohorts). **e–h**, Selected examples of the correlation of anti-SARS-CoV-2 RBD binding total Ig with IFN $\gamma$  T cell response to ancestral SARS-CoV-2 spike at pre-V2 (**e, g**) and post-V2 (**f, h**) timepoints in group 1 (all disease groups) (**e, f**) and


ANCA-associated vasculitis on rituximab patients (**g, h**). Unpaired statistical comparisons (**b, c, d**) were assessed with a Kruskal–Wallis test with post hoc Dunn's testing (adjusted alpha = 0.003). Paired statistical tests were performed with two-sided Wilcoxon's rank-sum test with Bonferroni correction (adjusted alpha = 0.0125). **a–c**, \* indicates statistically significant by Bonferroni-adjusted alpha. \*\*\*adjusted  $P < 0.001$ , \*\*\*\*adjusted  $P < 0.0001$ . **e–h**, Correlations are Spearman's rank-sum correlation, and fitted line is presented. **b**, Boxes represent median and IQR; whiskers represent  $\pm 1.5 \times$  IQR. AAV, ANCA-associated vasculitis; CD, Crohn's disease; CLD, chronic liver disease; HD, hemodialysis; HD on IS, hemodialysis on immunosuppression; HM, hematological malignancy; IA, inflammatory arthritis; L-AI, autoimmune hepatitis; L-Cir, liver cirrhosis; L-Tr, liver transplant; Nucleocapsid negative, N-ve; Nucleocapsid positive, N+ve; NS, not significant; RC, rheumatic conditions; SC, solid cancer; UC, ulcerative colitis.

than biological therapies) were associated with a suboptimal serological response to vaccination, and, therefore, all patients receiving these therapies should be considered at risk for severe COVID-19.

In evaluating the effect of CCC cross-reactive antibodies on vaccines responsiveness, only HCoV-OC43 antibody titers (the CCC with the highest homology to SARS-CoV-2 spike<sup>58-60</sup>) were predictive







**Fig. 4 | Predictors of anti-SARS-CoV-2 spike antibody and T cell responses after two doses of COVID-19 vaccine.** Forest plot of multivariable logistic regression model fitted on post-V2 anti-SARS-CoV-2 RBD-binding total Ig antibody (whole group 1 and group 2 ( $n = 2,204$ ) and matched healthy controls ( $n = 225$ )) (a) and IFN $\gamma$  T cell responses (group 1 ( $n = 645$ ) and matched healthy controls ( $n = 189$ )) (b). OR of anti-SARS-CoV-2 RBD-binding total Ig >380 AU ml<sup>-1</sup> (a) and OR of anti-SARS-CoV-2 spike IFN $\gamma$  T cell response  $\geq 4$  SFCs per 10<sup>6</sup> PBMCs (b). Center of error bars represents OR, and whiskers represent 95% CI. *P* values


are outputs of multivariable logistic regression model.  $P < 0.05$  is significant and marked with blue lines. AAV, ANCA-associated vasculitis; CD, Crohn's disease; DMARDs, disease-modifying anti-rheumatic drugs; HD, hemodialysis; HD on IS, hemodialysis on immunosuppression; HM, hematological malignancy; IA, inflammatory arthritis; L-Al, autoimmune hepatitis; L-Cir, liver cirrhosis; L-Tr, liver transplant; OSFC, zero spot forming cells; SC, solid cancer; UC, ulcerative colitis; wks, weeks.

of serological response to the first vaccine only. This shows that cross-reactive memory immune responses do not contribute to vaccine responsiveness once a significant SARS-CoV-2 memory pool has been established in immune-suppressed patients. Although T cell cross-reactivity using whole spike antigens against Omicron was maintained, antibody responses against all VOCs were decreased in both blood and saliva, and, at Roche anti-RBD Ig titers below 4,000 AU ml<sup>-1</sup>, most patients failed to neutralize Omicron BA.1. We suggest that this antibody titer threshold be explored in subsequent studies as a possible correlate of protection in immune-suppressed patients. New COVID-19 vaccine boosting regimens that account for the loss of recognition against emerging SARS-CoV-2 variants are likely to be particularly required for clinically vulnerable patients.

The strengths of our study include recruitment of a large number of patients and healthy controls, a wide range of disease phenotypes, national geographical spread, robust standardized procedures and

standardization of timepoints with infection outcomes. Limitations include missing baseline data (due to the very rapid delivery of the vaccination program in vulnerable groups), no randomization for vaccine type, controls recruited in a separate study and heterogeneity of disease duration, severity, therapeutic regimen and comorbidities within groups. Additionally, OCTAVE assessed responses after two COVID-19 vaccines, whereas vulnerable patients have now typically received three or more vaccines. Nevertheless, because all healthy volunteers generate high-magnitude immune responses after two vaccines, the head-to-head comparison to assess relative vaccine effectiveness in disease cohorts compared to healthy controls remains informative.

Overall, our data are reassuring because most patients generated robust T cell responses and moderate serological responses and had mild COVID-19. However, the fact that some patients groups fail to generate high-magnitude immune responses, and the association of these with severe COVID-19, highlights the importance of developing



strategies to (1) maximize cellular and humoral immune responses with new vaccine strategies; (2) protect patients by alternative therapeutic strategies<sup>61-64</sup>; and (3) continue to identify predictors of suboptimal

vaccine responsiveness in immune-suppressed patients. Further studies on the effects of third and fourth vaccine doses alongside clinical outcomes are required. A national study (OCTAVE DUO) assessing

**Fig. 5 | SARS-CoV-2 infection and severity after COVID-19 vaccination.**

**a,b**, COVID-19 incidence-free progression over time after second vaccine and infection rate per 1,000 double-vaccinated days, split by post-V2 anti-SARS-CoV-2 RBD-binding total Ig responder status ( $n = 1,617$ ) (**a**) and post-V2 IFN $\gamma$  T cell response to SARS-CoV-2 spike ( $n = 359$ ) (**b**). Total number (**c,e**) and proportion (**d,f**) of SARS-CoV-2 infections stratified by COVID-19 disease severity and SARS-CoV-2 RBD-binding total Ig ( $n = 440$ ) (**c,d**) or SARS-CoV-2 spike IFN $\gamma$  T cell ( $n = 98$ ) (**e,f**) response status. Severity data are shown at 6-month post-V2 and 12-month post-V1 timepoints and both timepoints combined, including only patients with known infection severity. **g,h**, Magnitude of post-V2 SARS-CoV-2 RBD-binding total Ig ( $n = 2,191$ ) (**g**) and SARS-CoV-2 spike IFN $\gamma$  T cell response ( $n = 573$ )

(**h**) stratified by COVID-19 infection/severity—includes all non-hospitalized individuals with or without SARS-CoV-2 infection (infected and uninfected, non-hospitalized) and infected individuals who were not hospitalized with COVID-19 (infected, non-hospitalized) and individuals who were hospitalized or died with COVID-19 (infected, hospitalized). Fisher's exact tests (**d,f**) or two-sided Mann-Whitney rank-sum statistical tests (**g,h**) were used without correction for multiple comparisons. **a,b**, Lines represent COVID-19-free progression, and shading represents 95% CI. **g,h**, Boxes represent median and IQR; whiskers represent  $\pm 1.5 \times$  IQR. \* $P < 0.05$ , \*\*\*\* $P < 0.0001$ . Ab, anti-SARS-CoV-2 RBD-binding total Ig; Hosp-Oxygen, hospitalized with COVID-19 and required oxygen; Hosp-No Oxygen, hospitalized with COVID-19 but did not require oxygen; mo, month.

third vaccine doses in immune-suppressed patients has fully recruited (ISRCTN15354495). Although our data may be directly used to inform COVID-19-related vaccination strategies in vulnerable patients, the future use of stored biological samples to evaluate biological pathways in secondary immune deficiency, alongside the relative risks of COVID-19 disease severity and immune responsiveness in disease subgroups, may inform clinical strategies in relation to vaccines or infection susceptibility in general.

**Online content**

Any methods, additional references, Nature Portfolio reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at <https://doi.org/10.1038/s41591-023-02414-4>.

**References**

- Haas, E. J. et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. *Lancet* **397**, 1819–1829 (2021).
- Pritchard, E. et al. Impact of vaccination on new SARS-CoV-2 infections in the United Kingdom. *Nat. Med.* **27**, 1370–1378 (2021).
- Nyberg, T. et al. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. *Lancet* **399**, 1303–1312 (2022).
- Office for National Statistics. People with long-term health conditions, UK: January to December 2019. <https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/adhocs/11478peoplewithlongtermhealthconditionsukjanuarytodecember2019> (2020).
- Marjot, T. et al. Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: an international registry study. *J. Hepatol.* **74**, 567–577 (2021).
- Clift, A. K. et al. Living risk prediction algorithm (QCOVID) for risk of hospital admission and mortality from coronavirus 19 in adults: national derivation and validation cohort study. *BMJ* **371**, m3731 (2020).
- Lin, S. et al. Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab. *Nat. Commun.* **13**, 1379 (2022).
- Redjoul, R., Le Bouter, A., Beckerich, F., Fourati, S. & Maury, S. Antibody response after second BNT162b2 dose in allogeneic HSCT recipients. *Lancet* **398**, 298–299 (2021).
- Mahil, S. K. et al. The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study. *Lancet Rheumatol.* **3**, e627–e637 (2021).
- Maneikis, K. et al. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study. *Lancet Haematol.* **8**, e583–e592 (2021).
- Alexander, J. L. et al. COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study. *Lancet Gastroenterol. Hepatol.* **7**, 342–352 (2022).
- Kennedy, N. A. et al. Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD. *Gut* **70**, 1884–1893 (2021).
- Thuluvath, P. J., Robarts, P. & Chauhan, M. Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients and those with chronic liver diseases. *J. Hepatol.* **75**, 1434–1439 (2021).
- Murray, S. M. et al. Impaired humoral and cellular response to primary COVID-19 vaccination in patients less than 2 years after allogeneic bone marrow transplant. *Br. J. Haematol.* **198**, 668–679 (2022).
- Carr, E. J. et al. Neutralising antibodies after COVID-19 vaccination in UK haemodialysis patients. *Lancet* **398**, 1038–1041 (2021).
- Prendecki, M. et al. Immunological responses to SARS-CoV-2 vaccines in kidney transplant recipients. *Lancet* **398**, 1482–1484 (2021).
- Jiménez, M. et al. Cellular and humoral immunogenicity of the mRNA-1273 SARS-CoV-2 vaccine in patients with hematologic malignancies. *Blood Adv.* **6**, 774–784 (2022).
- Dhakar, B. et al. Response to SARS-CoV-2 vaccination in patients after hematopoietic cell transplantation and CAR T-cell therapy. *Blood* **138**, 1278–1281 (2021).
- Bergman, P. et al. Safety and efficacy of the mRNA BNT162b2 vaccine against SARS-CoV-2 in five groups of immunocompromised patients and healthy controls in a prospective open-label clinical trial. *EBioMedicine* **74**, 103705 (2021).
- Furer, V. et al. Immunogenicity induced by two and three doses of the BNT162b2 mRNA vaccine in patients with autoimmune inflammatory rheumatic diseases and immunocompetent controls: a longitudinal multicentre study. *Ann. Rheum. Dis.* **81**, 1594–1602 (2022).
- Spanjaart, A. M. et al. Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group. *Leukemia* **35**, 3585–3588 (2021).
- Ljungman, P. et al. COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey. *Leukemia* **35**, 2885–2894 (2021).
- Lim, S. H. et al. Antibody responses after SARS-CoV-2 vaccination in patients with lymphoma. *Lancet Haematol.* **8**, e542–e544 (2021).

24. Carr, E. J. et al. Omicron neutralising antibodies after COVID-19 vaccination in haemodialysis patients. *Lancet* **399**, 800–802 (2022).
25. Benning, L. et al. Neutralizing antibody response against the B.1.617.2 (delta) and the B.1.1.529 (omicron) variants after a third mRNA SARS-CoV-2 vaccine dose in kidney transplant recipients. *Am. J. Transpl.* **22**, 1873–1883 (2022).
26. Whitaker, H. J. et al. Pfizer-BioNTech and Oxford AstraZeneca COVID-19 vaccine effectiveness and immune response amongst individuals in clinical risk groups. *J. Infect.* **84**, 675–683 (2022).
27. Hippisley-Cox, J. et al. Risk prediction of covid-19 related death and hospital admission in adults after covid-19 vaccination: national prospective cohort study. *BMJ* **374**, n2244 (2021).
28. Turtle, L. et al. Outcome of COVID-19 in hospitalised immunocompromised patients: an analysis of the WHO ISARIC CCP-UK prospective cohort study. *PLoS Med.* **20**, e1004086 (2023).
29. Agrawal, U. et al. Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters: pooled analysis of national prospective cohort studies of 30 million individuals in England, Northern Ireland, Scotland, and Wales. *Lancet* **400**, 1305–1320 (2022).
30. Ward, I. L. et al. Risk of covid-19 related deaths for SARS-CoV-2 omicron (B.1.1.529) compared with delta (B.1.617.2): retrospective cohort study. *BMJ* **378**, e070695 (2022).
31. Lee, L. Y. W. et al. Association of SARS-CoV-2 spike protein antibody vaccine response with infection severity in patients with cancer: a national COVID cancer cross-sectional evaluation. *JAMA Oncol.* **9**, 188–196 (2022).
32. Ward, I. L. et al. Risk of covid-19 related deaths for SARS-CoV-2 omicron (B.1.1.529) compared with delta (B.1.617.2): retrospective cohort study. *BMJ* **378**, e070695 (2022).
33. Molodtsov, I. A. et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific T cells and antibodies in Coronavirus Disease 2019 (COVID-19) protection: a prospective study. *Clin. Infect. Dis.* **75**, e1–e9 (2022).
34. Khoury, D. S. et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. *Nat. Med.* **27**, 1205–1211 (2021).
35. Feng, S. et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. *Nat. Med.* **27**, 2032–2040 (2021).
36. Addetia, A. et al. Neutralizing antibodies correlate with protection from SARS-CoV-2 in humans during a fishery vessel outbreak with a high attack rate. *J. Clin. Microbiol.* **58**, e02107–e02120 (2020).
37. Gilbert, P. B. et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. *Science* **375**, 43–50 (2022).
38. Earle, K. A. et al. Evidence for antibody as a protective correlate for COVID-19 vaccines. *Vaccine* **39**, 4423–4428 (2021).
39. Menni, C. et al. COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study. *Lancet Infect. Dis.* **22**, 1002–1010 (2022).
40. Andrews, N. et al. Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England. *Nat. Med.* **28**, 831–837 (2022).
41. Scurr, M. J. et al. Magnitude of venous or capillary blood-derived SARS-CoV-2-specific T cell response determines COVID-19 immunity. *Nat. Commun.* **13**, 5422 (2022).
42. Skelly, D. T. et al. Two doses of SARS-CoV-2 vaccination induce robust immune responses to emerging SARS-CoV-2 variants of concern. *Nat. Commun.* **12**, 5061 (2021).
43. Ahmed, S. et al. Postvaccination antibody titres predict protection against COVID-19 in patients with autoimmune diseases: survival analysis in a prospective cohort. *Ann. Rheum. Dis.* **81**, 868–874 (2022).
44. Shields, A. M. et al. Impact of vaccination on hospitalization and mortality from COVID-19 in patients with primary and secondary immunodeficiency: the United Kingdom experience. *Front. Immunol.* **13**, 984376 (2022).
45. Boudhabhay, I. et al. COVID-19 outbreak in vaccinated patients from a haemodialysis unit: antibody titres as a marker of protection from infection. *Nephrol. Dial. Transpl.* **37**, 1357–1365 (2022).
46. Bell, S. et al. The impact of vaccination on incidence and outcomes of SARS-CoV-2 infection in patients with kidney failure in Scotland. *J. Am. Soc. Nephrol.* **33**, 677–686 (2022).
47. Wall, E. C. et al. AZD1222-induced neutralising antibody activity against SARS-CoV-2 Delta VOC. *Lancet* **398**, 207–209 (2021).
48. Ward, H. et al. Population antibody responses following COVID-19 vaccination in 212,102 individuals. *Nat. Commun.* **13**, 907 (2022).
49. van Gils, M. J. et al. Antibody responses against SARS-CoV-2 variants induced by four different SARS-CoV-2 vaccines in health care workers in the Netherlands: a prospective cohort study. *PLoS Med.* **19**, e1003991 (2022).
50. Stuart, A. S. V. et al. Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial. *Lancet* **399**, 36–49 (2022).
51. Parry, H. et al. Differential immunogenicity of BNT162b2 or ChAdOx1 vaccines after extended-interval homologous dual vaccination in older people. *Immun. Ageing* **18**, 34 (2021).
52. McDonald, I., Murray, S. M., Reynolds, C. J., Altmann, D. M. & Boyton, R. J. Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2. *NPJ Vaccines* **6**, 74 (2021).
53. Martin, P. et al. Comparison of immunogenicity and clinical effectiveness between BNT162b2 and ChAdOx1 SARS-CoV-2 vaccines in people with end-stage kidney disease receiving haemodialysis: a prospective, observational cohort study. *Lancet Reg. Health Eur.* **21**, 100478 (2022).
54. Foster, W. S. et al. Tfh cells and the germinal center are required for memory B cell formation & humoral immunity after ChAdOx1 nCoV-19 vaccination. *Cell Rep. Med.* **3**, 100845 (2022).
55. Chen, J. S. et al. High-affinity, neutralizing antibodies to SARS-CoV-2 can be made without T follicular helper cells. *Sci. Immunol.* **7**, eabl5652 (2022).
56. Klemis, V. et al. Comparative immunogenicity and reactogenicity of heterologous ChAdOx1-nCoV-19-priming and BNT162b2 or mRNA-1273-boosting with homologous COVID-19 vaccine regimens. *Nat. Commun.* **13**, 4710 (2022).
57. Schmidt, T. et al. Cellular immunity predominates over humoral immunity after homologous and heterologous mRNA and vector-based COVID-19 vaccine regimens in solid organ transplant recipients. *Am. J. Transpl.* **21**, 3990–4002 (2021).
58. Anderson, E. M. et al. Seasonal human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not associated with protection. *Cell* **184**, 1858–1864 (2021).
59. Angyal, A. et al. T-cell and antibody responses to first BNT162b2 vaccine dose in previously infected and SARS-CoV-2-naive UK health-care workers: a multicentre prospective cohort study. *Lancet Microbe* **3**, e21–e31 (2022).
60. Murray, S. M. et al. The impact of pre-existing cross-reactive immunity on SARS-CoV-2 infection and vaccine responses. *Nat. Rev. Immunol.* **23**, 304–316 (2023).



61. Beigel, J. H. et al. Remdesivir for the treatment of Covid-19—final report. *N. Engl. J. Med.* **383**, 1813–1826 (2020).
62. O'Brien, M. P. et al. Subcutaneous REGEN-COV antibody combination to prevent Covid-19. *N. Engl. J. Med.* **385**, 1184–1195 (2021).
63. Abani, O. et al. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. *Lancet* **397**, 1637–1645 (2021).
64. Yu, L.-M. et al. Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. *Lancet* **398**, 843–855 (2021).

**Publisher's note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2023

**Eleanor Barnes**<sup>1,2,44</sup>, **Carl S. Goodyear**<sup>3,44</sup>, **Michelle Willicombe**<sup>4,44</sup>, **Charlotte Gaskell**<sup>5,44</sup>, **Stefan Siebert**<sup>3</sup>, **Thushan I de Silva**<sup>6</sup>, **Sam M. Murray**<sup>1</sup>, **Daniel Rea**<sup>5</sup>, **John A. Snowden**<sup>7</sup>, **Miles Carroll**<sup>8</sup>, **Sarah Pirrie**<sup>5</sup>, **Sarah J. Bowden**<sup>5</sup>, **Susanna J. Dunachie**<sup>1,2</sup>, **Alex Richter**<sup>9</sup>, **Zixiang Lim**<sup>1</sup>, **Jack Satsangi**<sup>1</sup>, **Gordon Cook**<sup>10</sup>, **Ann Pope**<sup>5</sup>, **Ana Hughes**<sup>5</sup>, **Molly Harrison**<sup>5</sup>, **Sean H. Lim**<sup>11</sup>, **Paul Miller**<sup>12,45</sup>, **Paul Klenerman**<sup>1,2</sup>, **PITCH consortium\***, **Neil Basu**<sup>3</sup>, **Ashley Gilmour**<sup>3</sup>, **Sophie Irwin**<sup>1</sup>, **Georgina Meacham**<sup>1</sup>, **Thomas Marjot**<sup>1</sup>, **Stavros Dimitriadis**<sup>1</sup>, **Peter Kelleher**<sup>13</sup>, **Maria Prendecki**<sup>4</sup>, **Candice Clarke**<sup>4</sup>, **Paige Mortimer**<sup>4</sup>, **Stacey McIntyre**<sup>4</sup>, **Rachael Selby**<sup>7</sup>, **Naomi Meardon**<sup>6</sup>, **Dung Nguyen**<sup>8</sup>, **Tom Tipton**<sup>8</sup>, **Stephanie Longet**<sup>8</sup>, **Stephen Laidlaw**<sup>8</sup>, **Kim Orchard**<sup>14</sup>, **Georgina Ireland**<sup>15</sup>, **CONSENSUS\***, **David Thomas**<sup>4,44</sup>, **Pamela Kearns**<sup>5,16,44</sup>, **Amanda Kirkham**<sup>5,44</sup>, **Iain B. McInnes**<sup>3,44</sup> ✉ & **OCTAVE Collaborative Group\***

<sup>1</sup>Nuffield Department of Medicine, University of Oxford, Oxford, UK. <sup>2</sup>Oxford University Hospitals NHS Foundation Trust, Oxford, UK. <sup>3</sup>College of Medical, Veterinary & Life Sciences, University of Glasgow, Glasgow, UK. <sup>4</sup>Centre for Inflammatory Disease, Department of Immunology and Inflammation, Imperial College London, Hammersmith Campus, London, UK. <sup>5</sup>Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham, Edgbaston, Birmingham, UK. <sup>6</sup>Department of Infection, Immunity and Cardiovascular Disease, The Medical School, The University of Sheffield, Sheffield, UK. <sup>7</sup>Department of Haematology, Sheffield Teaching Hospitals NHS Foundation Trust, Royal Hallamshire Hospital, Sheffield, UK. <sup>8</sup>Wellcome Centre for Human Genetics, University of Oxford, Oxford, UK. <sup>9</sup>Clinical Immunology Service, University of Birmingham, Edgbaston, Birmingham, UK. <sup>10</sup>National Institute for Health Research, Leeds MIC, University of Leeds, Leeds, UK. <sup>11</sup>Centre for Cancer Immunology, University of Southampton, Southampton, UK. <sup>12</sup>British Society of Blood and Marrow Transplantation and Cellular Therapy, Guy's Hospital, London, UK. <sup>13</sup>Department of Infectious Diseases, Imperial College London, School of Medicine Chelsea and Westminster Hospital, London, UK. <sup>14</sup>Department of Haematology, University Hospital Southampton NHS Foundation Trust, Southampton, UK. <sup>15</sup>UK Health Security Agency (UKHSA), Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency, London, UK. <sup>16</sup>National Institute for Health Research Birmingham Biomedical Research Centre, Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, UK. <sup>44</sup>These authors contributed equally: Eleanor Barnes, Carl S. Goodyear, Michelle Willicombe, Charlotte Gaskell, David Thomas, Pamela Kearns, Amanda Kirkham, Iain B. McInnes. <sup>45</sup>Deceased: Paul Miller. \*Lists of authors and their affiliations appear at the end of the paper. ✉e-mail: [Iain.McInnes@glasgow.ac.uk](mailto:Iain.McInnes@glasgow.ac.uk)

## PITCH consortium

**Susanna J. Dunachie**<sup>1,2</sup>, **Paul Klenerman**<sup>1,2</sup>, **Eleanor Barnes**<sup>1,2,44</sup>, **Alex G. Richter**<sup>9</sup>, **Thushan I de Silva**<sup>6</sup>, **Alex Mentzer**<sup>1,8</sup>, **Alexandra Deeks**<sup>1</sup>, **Anni Jansen**<sup>1</sup>, **Anthony Brown**<sup>1</sup>, **Chris Conlon**<sup>1</sup>, **Chris Dold**<sup>17</sup>, **Christopher J. A. Duncan**<sup>18</sup>, **Donal Skelly**<sup>19</sup>, **Barbara Kronsteiner**<sup>1</sup>, **Priyanka Abraham**<sup>1</sup>, **Eloise Phillips**<sup>1</sup>, **Katie Jeffery**<sup>2</sup>, **Lance Turtle**<sup>20</sup>, **Lisa Frending**<sup>1</sup>, **Lizzie Stafford**<sup>1</sup>, **Mohammad Ali**<sup>1</sup>, **Patpong Rongkard**<sup>1</sup>, **Rebecca Payne**<sup>18</sup>, **Sandra Adele**<sup>1</sup>, **Simon Travis**<sup>1</sup>, **Siobhan Gardiner**<sup>1</sup>, **Sue L. Dobson**<sup>20</sup>, **Tom Malone**<sup>1</sup>, **Sagida Bibi**<sup>17</sup>, **Miles Carroll**<sup>1</sup>, **Sian Faustini**<sup>21</sup>, **Sarah Foulkes**<sup>22</sup>, **John Frater**<sup>1</sup>, **Victoria Hall**<sup>22</sup>, **Susan Hopkins**<sup>22</sup>, **Jasmin Islam**<sup>22</sup>, **Teresa Lambe**<sup>17</sup>, **Stephanie Longet**<sup>1</sup>, **Shona C. Moore**<sup>20</sup>, **Ashley Otter**<sup>22</sup>, **Sarah L. Rowland-Jones**<sup>23</sup>, **James E. D. Thaventhir**<sup>24</sup> & **Daniel G. Wootton**<sup>20</sup>

<sup>17</sup>Oxford Vaccine Group, Department of Paediatrics, University of Oxford, Oxford, UK. <sup>18</sup>Translational and Clinical Research Institute, Newcastle University, Newcastle, UK. <sup>19</sup>Nuffield Dept of Clinical Neurosciences, University of Oxford, Oxford, UK. <sup>20</sup>Institute of Infection, Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK. <sup>21</sup>Institute for Immunology and Immunotherapy, College of Medical and Dental Science, University of Birmingham, Birmingham, UK. <sup>22</sup>Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency, London, UK. <sup>23</sup>Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK. <sup>24</sup>MRC Toxicology Unit, University of Cambridge, Cambridge, UK.

## CONSENSUS

Kevin Brown<sup>22</sup> & Gayatri Amirthalingam<sup>22</sup>

## OCTAVE Collaborative Group

Richard Beesley<sup>25</sup>, Vicky Churchill<sup>25</sup>, Holly Loughton<sup>25</sup>, Elspeth Insch<sup>25</sup>, Eilean MacDonald<sup>25</sup>, Gary Middleton<sup>26</sup>, Lucinda Billingham<sup>5</sup>, Faye Lowe<sup>5</sup>, Sophia Magwaro<sup>5</sup>, Saly Al-Taei<sup>27</sup>, Maxine Arnott<sup>28</sup>, Louise Bennett<sup>28</sup>, James Brock<sup>28</sup>, Victora Keillor<sup>28</sup>, Andrew Melville<sup>28</sup>, Lisa Melville<sup>28</sup>, Samantha Miller<sup>28</sup>, Aurelie Najm<sup>28</sup>, Caron Paterson<sup>28</sup>, Lewis Rodgers<sup>28</sup>, Matthew Rutherford<sup>28</sup>, Suzann Rundell<sup>28</sup>, Emily Smith<sup>28</sup>, Lynn Stewart<sup>28</sup>, Flavia Sunzini<sup>28</sup>, Andrew Tong<sup>28</sup>, Kieran Woolcock<sup>28</sup>, Faisal Basheer<sup>29</sup>, Charles Crawley<sup>29</sup>, Ram Malladi<sup>29</sup>, Andrew King<sup>29</sup>, Sophie Lockey<sup>29</sup>, Ben Uttenthal<sup>29</sup>, Mickey B. C. Koh<sup>30</sup>, Sam Hansford<sup>23</sup>, Gurjinder Sandhar<sup>23</sup>, Murali Kesavan<sup>31</sup>, Celia Moore<sup>32</sup>, Pinelopi Manousou<sup>32</sup>, Gareth Hahn<sup>32</sup>, Benjamin Mullish<sup>32</sup>, Maria Atta<sup>33</sup>, Sarah Gleeson<sup>34</sup>, Liz Lightstone<sup>34</sup>, Paul Martin<sup>34</sup>, Stephen McAadoo<sup>34</sup>, Tina Thomson<sup>34</sup>, Daniele Avenoso<sup>35</sup>, Robin Sanderson<sup>35</sup>, Claire Taylor<sup>36</sup>, Khushpreet Bhandal<sup>37</sup>, Diana Hull<sup>37</sup>, Palak Trivedi<sup>38</sup>, Andrew Filer<sup>39</sup>, Erin Hurst<sup>40</sup>, Amy Publicover<sup>40</sup>, Katy Scouse<sup>40</sup>, Jem Chalk<sup>1</sup>, Daniel Hanke<sup>1</sup>, Josef Hanke<sup>1</sup>, Saoirse Healy<sup>8</sup>, Stephen Laidlaw<sup>8</sup>, Stephanie Longet<sup>1</sup>, Nicholas Provine<sup>1</sup>, Sarah Thomas<sup>1</sup>, Victoria Walker<sup>1</sup>, Zay Win<sup>1</sup>, Doreen Trown<sup>41</sup>, Patricia Faria<sup>42</sup>, Julie Chackathayil<sup>42</sup>, Clare Hutchison<sup>43</sup> & Deborah Richardson<sup>43</sup>

<sup>25</sup>Patient and Public Representatives on the Trial Management Group, Birmingham, UK. <sup>26</sup>Cancer Centre, University Hospitals Birmingham, NHS Foundation Trust, Birmingham, UK. <sup>27</sup>Clinical Immunology Service, University of Birmingham, Edgbaston, Birmingham, UK. <sup>28</sup>University of Glasgow, Glasgow, UK. <sup>29</sup>Department of Haematology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK. <sup>30</sup>Infection and Immunity Clinical Academic Group, St. George's, University of London; Department of Haematology, St. George's University Hospital NHS Foundation Trust, London, UK. <sup>31</sup>Department of Oncology, Cancer and Haematology Centre, Churchill Hospital, Headington, Oxford, UK. <sup>32</sup>Division of Digestive Diseases, Department of Metabolism, Digestion and Reproduction, Faculty of Medicine, Imperial College London, London, UK. <sup>33</sup>Department of Haematology, Hammermith Hospital, London, UK. <sup>34</sup>Imperial College Healthcare NHS Trust, Hammersmith Hospital, London, UK. <sup>35</sup>King's College Hospital NHS Foundation Trust, London, UK. <sup>36</sup>Leeds Institute of Medical Research, University of Leeds, Leeds, UK. <sup>37</sup>Liver Research Delivery Team, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK. <sup>38</sup>National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre, Centre for Liver and Gastrointestinal Research, Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK. <sup>39</sup>National Institute for Health Research (NIHR) Birmingham Biomedical Research Centre and NIHR Clinical Research Facility, Institute of Inflammation and Ageing, University of Birmingham and University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK. <sup>40</sup>Northern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne, UK. <sup>41</sup>Sheffield Teaching Hospitals NHS Foundation Trust, Royal Hallamshire Hospital, Sheffield, UK. <sup>42</sup>St. George's hospital and Medical School, St George's University Hospitals NHS Foundation Trust, London, UK. <sup>43</sup>University Hospital Southampton NHS Foundation Trust, Southampton General Hospital, Southampton, UK.



## Methods

### Trial design and oversight

The OCTAVE trial is a multi-center, multi-disease, prospective cohort trial of the immune response to SARS-CoV-2 vaccination in patients receiving COVID-19 vaccination as part of routine, publicly funded National Health Service (NHS) care. The trial is a collaboration between the universities of Birmingham, Glasgow, Imperial College London, Oxford and Sheffield and is coordinated by the Cancer Research UK Clinical Trials Unit (CRCTU) at the University of Birmingham, which is the sponsor. The trial is conducted in accordance with Good Clinical Practice (GCP) guidelines. It was approved by the UK Medicines and Healthcare Products Regulatory Agency (MHRA) on 5 February 2021 and by the London and Chelsea Research Ethics Committee (REC ref.: 21/HRA/0489) on 12 February 2021. The protocol has subsequently been amended eight times with five substantial amendments (with ethical approvals dated 3 March 2021, 19 April 2021, 24 December 2021 and 4 April 2022) and three non-substantial amendments: protocol versions dated 22 April 2021, 14 July 2021 and 10 September 2021. The trial is registered on [ISRCTN12821688](https://www.isrctn.com/ISRCTN12821688).

### Patients recruited into OCTAVE

Written informed consent was obtained from all participants. The trial is recruiting adult and pediatric patients. Adult patients in clinically vulnerable groups were recruited between 19 February 2021 and 1 October 2021 (last vaccine administered) based on the following eligibility criteria:

- Are eligible for vaccination by one of the SARS-CoV-2 vaccines approved by the MHRA, administered in accordance with national guidelines.
- Have not received their second dose of the vaccine for the 'deep immunophenotyping group' or have not passed the day 28 post-second vaccine dose timepoint (21–84 d after second vaccination) for the 'serology group'.
- Have an anticipated lifespan of 6 months or longer.
- Have a diagnosis belonging to one of the following disease groups: solid cancer; hematological malignancy; rheumatic inflammatory conditions (including ANCA-associated vasculitis on rituximab and inflammatory arthritis), chronic renal disease (including end-stage kidney disease (patients on hemodialysis and hemodialysis with immunosuppression) and kidney transplantation), chronic liver disease (including liver cirrhosis, liver disease on immunosuppressive therapy and liver transplantation), inflammatory bowel disease on immunosuppressive therapy (Crohn's disease, ulcerative colitis and undefined inflammatory bowel disease), HSCT patients and CAR-T therapies. CAR-T patients are those who most recently received CAR-T as treatment in their therapeutic course. Inclusion criteria are included in the trial protocol (Supplementary Appendix 1).

All patients who fulfilled the patient characteristics inclusion criteria could be enrolled into either study group. Investigators generally recruited patients into group 1 first where possible, before patients had received two vaccines as part of the rapid UK COVID-19 vaccine program. Some patients opted for group 2 because fewer study visits were involved (patient choice).

OCTAVE recruited 2,686 adult patients: 2,012 patients into the serology group and 674 patients into the deep immune phenotyping group (see Supplementary Table 21 for recruitment per site). The full protocol (Supplementary Appendix 1) is available in the supplementary material.

The deep immunophenotyping cohort was assessed pre-vaccine (baseline), pre-second vaccine dose (pre-V2), 28 d post-second vaccine dose (post-V2, within  $\pm 3$  d), 6 months post-second vaccine dose and 12 months after the first vaccine dose (as close to timepoints as

possible). The serology cohort was assessed 28 d post-second vaccine dose ( $-7/+56$  d) and followed up 6 months post-second vaccine dose and 12 months after the first vaccine dose (as close to timepoints as possible).

Anti-RBD total Ig immunogenicity data were available in 2,204 patients and 225 healthy controls. T cell data were available in 656 patients in the deep immunophenotyping cohort and in 210 controls. Infection data were available in 1,648 OCTAVE patients at the <6-month post-V2 timepoint and 1,613 OCTAVE patients at the 6-month post-V2 to 12-month post-V1 timepoint. Severity data were available in 93% of those infected. AEs were reported in 2,662 patients post-V1 and 2,669 OCTAVE patients post-V2. Detailed information regarding the number of samples included in each immunogenicity assays is available in Extended Data Fig. 1.

After trial entry, 66 adult participants were found to have been recruited at the wrong timepoint in accordance with the eligibility criteria: 'Have not received their second dose of the vaccine for the 'deep immunophenotyping group' or have not passed the day 28 post-second vaccine dose timepoint (21–84 d after second vaccination) for the 'serology group'; and, for 24 participants, trial consent was obtained after the collection of post-booster samples (although these patients were recruited into another ethically approved study with full consent) before trial consent in OCTAVE. This was reported to the MHRA as a serious breach, and patients were still included in the analysis.

### Outcome measures

The primary outcomes for this trial are the magnitude of the anti-SARS-CoV-2 IgG antibodies and the magnitude of the T cell responses to SARS-CoV-2 peptides after vaccination. The secondary outcome is the proportion of first-symptomatic, PCR-proven COVID-19 infection 14 d after V1 in participants without evidence of prior COVID-19 infection. The exploratory outcomes are described in detail in the protocol (Supplementary Appendix 1).

This manuscript represents the definitive analysis of the primary outcome for the adult cohort.

### Vaccine administration

Vaccine (BNT162b2 (Pfizer/BioNTech) or ChAdOx1 nCoV-19 vaccine) was administered in line with its temporary authorization under Regulation 174 of the Human Medicines Regulations 2012, the national recommendations and guidance of the Joint Committee on Vaccination and Immunisation (JCVI) and current standard NHS practice. The trial has no influence on the type of vaccine given or the timing of the booster vaccine delivery. Vaccines were administered both through NHS pathways and by OCTAVE study investigators. The interval between vaccines was in accordance with national recommendations and the guidance of the JCVI. As vaccines were being given to new patient populations, this study was registered with the MHRA (UK MHRA clinical trial authorization number: 21761/0365/001).

### AEs

AEs were captured up to 28 d after the second vaccine and were graded 1–5 using the Common Terminology Criteria for Adverse Events (CTCAE), version 4.03.

### Sample collection

Serum samples were collected 4 weeks post-second dose ( $-7/+14$  d) for all participants, alongside whole blood for the Oxford Immunotec assay, PBMCs and plasma, when feasible. Where available, baseline (pre-vaccine samples, including samples that may have been collected before recruitment to OCTAVE) or pre-second dose samples taken any time after V1 but before the second dose were included. All samples were collected in accordance with national regulations and requirements, including standard operating procedures for logistics and infrastructure. Samples were taken in appropriately licensed premises

and stored and transported in accordance with Human Tissue Authority guidelines and NHS Trust policies.

### Anti-SARS-CoV-2 Ig analysis

The magnitude of anti-SARS-CoV-2 antibodies was measured using the Roche Elecsys AntiSARS-CoV-2 S and Roche Elecsys AntiSARS-CoV-2 N assays by the UKHSA Laboratories at Porton Down. The Roche assay measures the presence and the amount of serum antibodies to the spike RBD antigen of SARS-CoV-2. Seroconversion is defined as a response equal to or greater than  $0.8 \text{ AU ml}^{-1}$ , and no response is defined as less than  $0.8 \text{ AU ml}^{-1}$ . Low response was defined on the Roche anti-RBD Ig assay after evaluation of the serological response to vaccine in healthy controls. A cutoff for low was defined as the upper value of the bottom decile of healthy controls.

### T-SPOT DISCOVERY SARS-CoV-2 assay

The magnitude of the T cell responses was measured using the T-SPOT DISCOVERY SARS-CoV-2 assay by Oxford Immunotec (<https://www.tspotdiscovery.com/>). Peptide pools representing the full spike (S) proteins, subunits S1 and S2, nucleocapsid and membrane, plus positive (phytohaemagglutinin) and negative controls were used to stimulate 250,000 PBMCs separated from fresh whole blood. IFN $\gamma$ -secreting T cells were enumerated on an automated plate reader. Final values were calculated by subtracting the negative control and multiplying by 4 to define the number of IFN $\gamma$ -secreting T cells per  $10^6$  PBMCs. Values greater than or equal to four IFN $\gamma$ -secreting T cells per  $10^6$  PBMCs were defined as a positive response. In the renal cohort (hemodialysis with immunosuppression and hemodialysis), the full spike peptide pool was not included in the assay at all timepoints. To generate equivalent data, the S1 and S2 values were combined, and a cutoff of four IFN $\gamma$ -secreting T cells per  $10^6$  PBMCs was used for positivity. There was strong correlation between S1 + S2 and full spike pools in this assay ( $r = 0.90$ ,  $P < 0.0001$ ) (Extended Data Fig. 8).

### IFN $\gamma$ T cell ELISpot assay

Frozen PBMCs were thawed, and the Human IFN $\gamma$  ELISpot Basic Kit (Mabtech, 3420-2A) at Oxford University laboratories was used, as in ref. 65, but using 200,000 cells per well in duplicate. For antigens, we used overlapping peptide pools (18-mers with 10 amino acid overlap, mimotopes) representing ancestral spike (S1 and S2), Omicron (B.1.1.529 and BA.1) spike (S1 and S2), ancestral membrane and nucleocapsid SARS-CoV-2 proteins and pools of ancestral or Omicron 18-mer peptides covering the mutated regions of Omicron at a final concentration of  $2 \mu\text{g ml}^{-1}$ . The mean spots of the negative control wells were subtracted from the test wells and then multiplied by 5 to give antigen-specific responses expressed as SFU per  $10^6$  PBMCs. Total spike responses were defined by adding S1 and S2 responses together.

### Meso Scale Discovery IgG, IgA and IgM binding assays

IgG, IgA and IgM responses to SARS-CoV-2, SARS-CoV-1 and seasonal coronaviruses were measured using a multiplexed Meso Scale Discovery (MSD) immunoassay: V-PLEX COVID-19 Coronavirus Panel 2 Kit (K15369U-2) from Meso Scale Diagnostics. IgG was measured in all group 1 participants at all available timepoints; IgA and IgM were measured in ulcerative colitis, Crohn's disease, liver transplant, autoimmune liver disease, cirrhosis, inflammatory arthritis and ANCA-associated vasculitis disease groups at all available timepoints. A MULTI-SPOT 96-well, 10-spot plate was coated with four SARS-CoV-2 antigens (spike, RBD, nucleoprotein and NTD) and SARS-CoV-1 spike trimer as well as spike proteins from seasonal human coronaviruses, OC43, HKU1, 229 E and NL63 and BSA. Antigens were spotted at  $200\text{--}400 \mu\text{g ml}^{-1}$  (MSD Coronavirus Plate 2). Multiplex MSD assays were performed as per the manufacturer's instructions. To measure IgG, IgA and IgM binding antibodies, 96-well plates were blocked with MSD Blocker A for 30 min. After washing with washing buffer, plasma samples diluted

1:1,000–10,000 in diluent buffer were added to wells, along with MSD standard or undiluted MSD internal controls. After a 2-h incubation and a washing step, detection antibody (MSD SULFO-TAG Anti-Human IgG, IgA or IgM Antibody, 1/200) was added. After washing, MSD GOLD Read Buffer B was added, and plates were read using a MESO SECTORS 600 Reader. The standard curve was established by fitting the signals from the standard using a four-parameter logistic model. Concentrations of samples were determined from the electrochemiluminescence signals by backfitting to the standard curve and multiplied by the dilution factor. Concentrations are expressed in  $\text{AU ml}^{-1}$ . Cutoffs were determined for each SARS-CoV-2 antigen (spike, RBD, nucleoprotein and NTD) based on 64 pre-SARS-CoV-2 pandemic sera (average concentration +  $3 \times$  standard deviation for IgG, IgA and IgM binding) (Supplementary Table 22). As samples were from UK individuals with low probability to have been exposed to SARS-CoV-1, a cutoff for SARS-CoV-1 spike was similarly determined.

Alternatively, IgG responses to SARS-CoV-2 variant spike antigens, including Wuhan (ancestral) strain, Alpha, Beta, Gamma, Delta and Omicron (BA.1), were similarly measured using a multiplexed V-PLEX SARS-CoV-2 Panel 23 Kit (K15567U-2) from Meso Scale Diagnostics.

### MSD ACE2 inhibition surrogate neutralization assay

V-PLEX SARS-CoV-2 Panel 23 Kit was used to measure the ability of oral fluid or serum samples to inhibit ACE2 binding to different variants of SARS-CoV-2 spike, including B lineage Wuhan-Hu-1 spike, B.1.1.7/Alpha, B.1.351/Beta, P.1/Gamma, B.1.617.2/Delta and B.1.1.529/BA.1/Omicron. Assays were performed as per the manufacturer's instructions with neat oral fluid samples or diluted sera. To measure ACE2 inhibition, 96-well MSD plates were blocked with MSD Blocker for 30 min. Plates were then washed in MSD washing buffer, and  $25 \mu\text{l}$  of undiluted oral fluid samples or diluted sera (1/10–1/100) were added to the plate. After 1-h incubation, recombinant human ACE2-SULFO-TAG was added to all wells. After a further 1 h, plates were washed, and MSD GOLD Read Buffer B was added; plates were then immediately read using a MESO SECTORS 600 Reader. Neutralizing activity was determined by measuring the presence of antibodies able to block the binding of ACE2 to SARS-CoV-2 spike proteins from Wuhan-Hu-1 spike, B.1.1.7/Alpha, B.1.351/Beta, P.1/Gamma, B.1.617.2/Delta and B.1.1.529/BA.1/Omicron and was expressed as percentage of ACE2 inhibition in comparison to the blanks on the same plate.

### Microneutralization assay

Sera were serially diluted in DMEM supplemented with 1% FBS from an initial dilution of 1:10 to 1:10,000. Equal volumes of diluted sera and SARS-CoV-2 virus (approximately 100 foci-forming units (FFU)) were combined and incubated for 30 min. Viruses used in this assay were Victoria (VIC01) and Omicron (B.1.1.529 (BA.1)). After incubation,  $100 \mu\text{l}$  of Vero E6 cells ( $4.5 \times 10^5$  per milliliter) was added to each well, and virus was allowed to infect the cells for 2 h at  $37^\circ\text{C}$  and 5%  $\text{CO}_2$ , followed by the addition of  $100 \mu\text{l}$  of carboxymethyl cellulose (1.5%) to each well. The plates were incubated for a further 20–22 h at  $37^\circ\text{C}$  and 5%  $\text{CO}_2$ . All assays were carried out in triplicate.

Cells were washed with  $200 \mu\text{l}$  of DPBS and then fixed with paraformaldehyde 4% v/v ( $100 \mu\text{l}$  per well) for 30 min at room temperature. Cells were permeabilized with Triton X-100 (2% in PBS) and then stained for SARS-CoV-2 nucleoprotein using a human monoclonal antibody (FB9B). Bound antibody was detected after incubation with a goat anti-human IgG HRP conjugate (Sigma-Aldrich) and, after TrueBlue Peroxidase Substrate (Insight Biotechnology) addition, imaged using an ELISpot reader. The  $\text{IC}_{50}$  was defined as the concentration of compound that reduced the FFU by 50% compared to the control wells.

### Clinical data

Clinical data were collected electronically from participating sites using a REDCap (Research Electronic Data Capture) database held at the CRCTU. Data collected on trial entry included sex, ethnicity, body

mass index (BMI), smoking status, medical history and details of prior COVID-19 infection. Details of disease cohort treatment, COVID-19 vaccination, AEs and subsequent COVID-19 infection were collected during the course of the trial.

### SARS-CoV-2 infection and disease severity

SARS-CoV-2 infection was captured at each study visit in all patients through to V1 + 12 months between 14 January 2021 and 17 October 2022. Symptomatic infection (SARS-CoV-2 confirmed using PCR assay or lateral flow antigen test) was captured through (1) direct patient interview at all follow-up visits; (2) systematic review of the electronic patient record and/or regional databases; and (3) telephone interviews as required. Infection with a given VOC was defined as COVID-19 infection within time epochs where the VOC was most prevalent in the UK: Alpha, 14 January 2021 (study start) to 24 May 2021; Delta, 24 May to 20 December 2021; and Omicron 20 December 2021 onwards based on UK prevalence (<https://covariants.org/>). Disease severity was recorded on all patients with infection where available. If two infections were reported after V2, then only the first infection was included in subsequent analysis ( $n = 9$ ).

### Control group

The healthy controls group was derived from participant data and samples from two sources: the UK PITCH cohort and the UKHSA CONSENSUS cohort<sup>66</sup>. PITCH is a prospective, multi-center study assessing T cell responses to COVID-19 natural infection and vaccination<sup>59</sup>. Healthcare worker participants received SARS-CoV-2 vaccination as part of workplace programs. PITCH is a sub-study of the SIREN study (trial ID: 252 ISRCTN11041050), which was approved by the Berkshire REC, Health Research 250 Authority (IRAS ID: 284460, REC ref.: 20/SC/0230), with PITCH recognized as a sub-study on 2 December 2020. Some participants were recruited under PITCH-aligned study protocols. In Oxford, participants were recruited under the GI Biobank Study 16/YH/0247, approved by the Yorkshire & The Humber–Sheffield REC on 29 July 2016, which was amended for this purpose on 8 June 2020. In Liverpool, some participants were recruited under the ‘Human immune responses to acute virus infections’ study (16/NW/0170), approved by the North West–Liverpool Central REC on 8 March 2016 and amended on 14 September 2020 and 4 May 2021. In Sheffield, participants were recruited under the Observational Biobanking study STHObs (18/YH/0441), which was amended for this study on 10 September 2020. This study was conducted in compliance with all relevant ethical regulations for work with human participants and according to the principles of the Declaration of Helsinki (2008) and GCP guidelines. Written informed consent was obtained from all participants enrolled in the study.

Data from 986 participants were available from the two cohorts. The healthy controls group was then sorted to ensure that all control data met the following criteria:

- A post-boost sample was available.
- Data relating to age, sex, prior COVID status and vaccination type were available.
- Samples were taken within the same timeframe defined for the OCTAVE participant samples.

After sorting, the healthy control group was matched to the OCTAVE patient group based on prior COVID status and vaccine type using a proportional matching method. The relevant participants for each group were then randomly selected from the available control data to match the four analysis groups:

- Complete OCTAVE dataset (deep immunophenotyping and serology groups together)
- OCTAVE deep immunophenotyping only
- OCTAVE serology group only
- OCTAVE renal disease group only

A separate analysis group was created for the renal disease group, as these patients did not have the full spike peptide pool tested on the T-SPOT DISCOVERY at all timepoints due to the timing of recruitment.

### Statistical analysis

**Dataset preparation.** A healthy control data pool comprising 986 participants (231 PITCH study and 755 UKHSA dataset) was sampled to create the healthy controls analysis group by matching, as closely as possible, the proportions of age, sex, prior COVID status and vaccination type, as observed in the OCTAVE recruits. ELISpot assay raw data required processing before analytical use; the control blank readings were subtracted from the sample readings, and any negative numbers were replaced with zero; the new values were then multiplied by 4 to give cell counts per million.

### Analysis

Descriptive statistics data are presented as number of observations with percentages and medians with interquartile ranges (IQRs), unless indicated otherwise. Data were questioned using two-sided statistical tests, including Kruskal–Wallis H test (as data non-normal) with post hoc Dunn’s testing for pairwise comparisons,  $\chi^2$  and Fisher’s exact tests where required. Where multiple testing occurred, *P* values were adjusted using Bonferroni corrections. Pearson’s correlations and logistic regressions investigated data relationships. COVID-19-free time post-second vaccination was estimated using the method of Kaplan and Meier (1958). Time was taken from date of the second vaccine to date last seen. COVID-19 events were taken as the date of confirmed SARS-CoV-2 infection or date of death confirmed as being COVID-19 related. The number of SARS-CoV-2 infection events per 1,000 d was calculated by using (total number of SARS-CoV-2 infections) / (total number of days at risk post-second vaccination)  $\times$  1,000 = number of SARS-CoV-2 infection events per 1,000 d. COVID-19 disease severity was defined as asymptomatic; symptomatic without hospitalization; hospitalization with COVID-19 without requirement of oxygenation; hospitalization with COVID-19 with requirement of oxygenation; admission to ITU with COVID-19; or death related to COVID-19. Data were visualised using various plot types: box and whisker with overlaid data points using the jitter function to aid interpretation; vertically stacked bar charts of percentages of response types (non-responder, low-responder and responder); scatter plots with Pearson’s correlation analysis line; connected scatter plot showing changes; and matrix (panel) correlation plots illustrating assay results. All analyses used the statistical package Stata version 17.0 (StataCorp), GraphPad Prism (version 9.4.0) or R (version 4.2.1) with RStudio 2022.02.3.

### Statistics and reproducibility

The OCTAVE trial is a multi-center, multi-disease, prospective observational cohort trial. Statistical analyses were completed, independently replicated and compared to initial results. No discrepancies were found. The sample size was based on an estimation of the number of participants who could be recruited within the short space of time required. An effect size calculation, based on a *t*-test, was done to provide information as to whether the number of recruits would be sufficient. Missing data were excluded from the analyses. No other data were omitted. As an observational study, experiments were not randomized, and investigators were not blinded to allocation.

### Reporting summary

Further information on research design is available in the Nature Portfolio Reporting Summary linked to this article.

### Data availability

Participant data and the associated supporting documentation will be available for requesting within 6 months after the publication of this manuscript. Details of our data request process are available on the



CRCTU website. Only scientifically sound proposals from appropriately qualified research groups will be considered for data sharing. The decision to release data will be made by the CRCTU Director's Committee, which will consider the scientific validity of the request, the qualifications and resources of the research group, the views of the Chief Investigator and the trial steering committee, consent arrangements, the practicality of anonymizing the requested data and contractual obligations. A data-sharing agreement will cover the terms and conditions of the release of trial data and will include publication requirements, authorship and acknowledgements and obligations for the responsible use of data. An anonymized encrypted dataset will be transferred directly using a secure method and in accordance with the University of Birmingham's IT guidance on encryption of datasets. Information on data requests, including a contact address and expected timeframe of requests, can be found at <https://www.birmingham.ac.uk/research/crctu/data-sharing-policy.aspx>.

### Code availability

Code is available upon reasonable request through the same process as data, as detailed on the CRCTU website: <https://www.birmingham.ac.uk/research/crctu/data-sharing-policy.aspx>.

### References

65. Payne, R. P. et al. Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine. *Cell* **184**, 5699–5714 (2021).
66. Amirthalingam, G. et al. Serological responses and vaccine effectiveness for extended COVID-19 vaccine schedules in England. *Nat. Commun.* **12**, 7217 (2021).

### Acknowledgements

We thank the patients who took part in the trial; the 35 investigators from 11 recruiting centers and their research staff members; colleagues at UK Health Security Agency (UKHSA), including Bassam Hallis, Cathy Rowe and Sue Charlton; and the staff from the Cancer Research UK Clinical Trials Unit (CRCTU), University of Birmingham, including P. Boateng, H. Doyle and J. Mason. We also acknowledge the British Society of Blood and Marrow Transplantation and Cellular Therapy and associated centers in the IMPACT network that contributed to the recruitment of patients for the study. The OCTAVE trial was sponsored by the University of Birmingham and supported by the National Core Studies Immunology (NCSI) program and funded by a grant from UK Research and Innovation (UKRI) administered by the Medical Research Council (grant reference number MC\_PC\_20031). It was designated an Urgent Public Health study by the National Institute of Health Research (NIHR). The trial was designed, initiated and conducted independently by the trial investigators and delivered by the CRCTU, University of Birmingham. PITCH was funded by the UK Department of Health and Social Care as part of the PITCH (Protective Immunity from T cells to Covid-19 in Health workers) Consortium, by UKRI as part of 'Investigation of proven vaccine breakthrough by SARS-CoV-2 variants in established UK healthcare worker cohorts: SIREN consortium & PITCH Plus Pathway' MR/W02067X/1, and with contributions from UKRI/NIHR through the UK Coronavirus Immunology Consortium (UK-CIC), the Huo Family Foundation and the NIHR (UKRIDHSC COVID-19 Rapid Response Rolling Call, grant reference number COV19-RECPLAS). Staff at the CRCTU are supported by a core funding grant from Cancer Research UK (C22436/A25354) and the IMPACT consortium. E.B. is an NIHR Senior Investigator. D.T. receives funding from a Wellcome-Beit Clinical Research Career Development Fellowship. G.C. received support for the study from NIHR infrastructure at Leeds, UK. M.W. receives funding from the Sidharth and Indira Burman Donation/Imperial (NIHR) Biomedical Research Centre. S.J.D. is funded by an NIHR Global Research Professorship (NIHR300791). T.d.S. is funded by a Wellcome Trust Intermediate Clinical Fellowship (110058/Z/15/Z).

We would like to acknowledge P. Moss, who led the NCSI program. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, the Department of Health and Social Care, Public Health England or the US Food and Drug Administration.

### Author contributions

I.B.M. is the Chief Investigator for the OCTAVE trial. E.B., C.S.G., I.B.M. and P. Kearns wrote the grant for funding. I.B.M., E.B., C.S.G. and P. Kearns, conceived and developed the idea for the trial. I.B.M., A.K., C.G., C.S.G., P. Kearns, S.J.B., D.R., E.B., G.C., M.W., S.S., T.d.S., Z.L., J.S., G.C., T.M., D.T. and J.A.S. wrote the trial protocol and developed the case report form for collection of clinical data. C.S.G., E.B. and M.C. developed the laboratory procedures. S.J.B., A.P., A.H., M.H., S.D. and P. Kearns managed the trial. A.K., C.G., C.S.G., E.B., T.d.S. and I.B.M. developed the statistical plan. C.G., A.K., S.P., S.M.M. and L.B. performed the statistical analysis. S.M.M., S.L., T.T., S.L. and D.N. performed the variant of concern analysis. S.M.M., G.M. and S.I. performed the in-house cellular experimental work. S.J.D. and P. Klenerman are the Chief Investigators of the PITCH study. All named authors contributed to the interpretation of the analyses and the writing of the paper. I.B.M., E.B., C.S.G., M.W., S.S., T.d.S., J.S., S.J.B., S.J.D., A.R., J.S., G.C., D.T., P. Kearns formed the Trial Management Group. All authors have approved the submitted version of the manuscript and have verified its accuracy.

### Competing interests

E.B. consults for AstaZeneca, Roche and Vaccitech and has patents in ChAdox1 HBV and HCV vaccines. I.B.M. receives consulting fees and honoraria from AbbVie, AstraZeneca, Bristol Myers Squibb, Boehringer Ingelheim, Cabaletta, Causeway Therapeutics, Celgene, Evelo, Gilead, Janssen, Pfizer, Novartis, Eli Lilly, Moonlake and UCB Pharma and research support from Bristol Myers Squibb, Boehringer Ingelheim, Celgene, Janssen, Novartis and UCB Pharma. C.S.G. has received research grants from AstraZeneca but unrelated to any of the work described in this manuscript. Furthermore, the funder had no specific role in the conceptualization, design, data collection, analysis, decision to publish or preparation of the manuscript. P. Klenerman was part of an advisory board for AstraZeneca for work unrelated to vaccines. L.L. acted as a paid advisor to Pfizer and AstraZeneca for work unrelated to vaccines and was on an advisory board for AstraZeneca for pre-exposure prophylaxis. L.L. is a Trustee of Kidney Research UK and is associated with the UK Kidney Association. The authors declare no other relevant conflicts of interest. The OCTAVE study group comprises investigators, sub-investigators and clinical trial staff. The PITCH consortium comprises investigators and sub-investigators in the UK Department of Health and Social Care-funded study.

### Additional information


**Extended data** is available for this paper at <https://doi.org/10.1038/s41591-023-02414-4>.

**Supplementary information** The online version contains supplementary material available at <https://doi.org/10.1038/s41591-023-02414-4>.


**Correspondence and requests for materials** should be addressed to Iain B. McInnes.

**Peer review information** *Nature Medicine* thanks Vivian Avelino-Silva, Ana Medeiros-Ribeiro and the other, anonymous, reviewer(s) for their contribution to the peer review of this work. Primary handling editor: Jennifer Sargent, in collaboration with the *Nature Medicine* team.

**Reprints and permissions information** is available at [www.nature.com/reprints](http://www.nature.com/reprints).



**Extended Data Fig. 1 | Recruitment and analysis overview of OCTAVE and healthy control groups.** Recruitment and analysis overview of OCTAVE and HC participants. MSD = MesoScale Discovery, Ig = Immunoglobulin, S = Spike, RBD = Receptor binding domain, N = Nucleocapsid.




Extended Data Fig. 2 | See next page for caption.




**Extended Data Fig. 2 | Binding IgA, IgG and IgM to SARS-CoV-2 Spike receptor binding domain (RBD) and N-terminal domain (NTD) measured by MSD assay.** Binding IgA, IgG and IgM to SARS-CoV-2 Spike (a) receptor binding domain (RBD) and (b) N-terminal domain (NTD) measured by MSD assay. IgG in all patients in group 1 at all available timepoints, IgA and IgM in all timepoints

from all group 1 participants in the IA, AAV, IBD, L-Tr, L-AI and L-Cir disease groups at the pre-V1 (Pre-V1), pre-V2 (Pre-V2) and post-V2 (Post V2) timepoints. Two-sided Mann-Whitney U test corrected for multiple comparisons by Bonferroni correction. \* = adjusted P value < 0.05, \*\* adjusted P value < 0.01, \*\*\*\* adjusted P value < 0.0001. Boxes represent median and IQR, whiskers represent +/- 1.5x IQR.




**Extended Data Fig. 3 | Correlation of vaccine induced IgG with baseline common cold coronavirus antibodies.** Correlation plot of pre first vaccine (Pre-V2) and post second vaccine (Post-V2) anti-SARS-CoV-2 Spike binding IgG (MSD Assay) against baseline (Pre-V1) common cold coronavirus spike IgG,


IgA and IgM antibodies. IgG data collected at baseline, Pre-V2 and Post-V2 in all participants in group 1. IgM and IgA collected in all group 1 participants in the UC, CD, L-Tr, L-AI, L-Cir, IA and AAV disease groups. Includes HCoV's - 229E, HKU1, NL63 and OC43. Pearson correlation. \*P < 0.05, \*\*P < 0.01.



**Extended Data Fig. 4 | Correlation of post-second vaccine immune assay responses.** Correlation plot of all assays used to evaluate serological and cellular responses on the 59 group 1 participants with deep immunophenotyping at the Post-V2 timepoint. Spearman rank sum test used.  $R^2$  depicted by area of circle and colour legend. \* P value < 0.05; \*\* P value < 0.01, \*\*\*: P value < 0.001.




**Extended Data Fig. 5 | Correlation of serum and salivary inhibition of ACE2 binding.** Spearman rank sum correlation of % inhibition of ACE2 by serum and saliva Ig at the post-V2 in immunocompromised individuals (n = 54).



**Extended Data Fig. 6 | Correlation of anti-RBD Ig titre against full-Spike IFNy ELISpot magnitude at the pre- and post-v2 timepoints in OCTAVE subgroups.** anti-SARS-CoV-2 RBD Ig titre (Roche assay) plotted against full-Spike IFNy ELISpot magnitude at the pre- and post-v2 timepoints in OCTAVE subgroups.


Solid cancer, Crohn's disease and Autologous-HSCT show positive correlations at pre-v2 but not post-v2. Inflammatory arthritis and liver cirrhosis sub-groups showed no significant correlation pre-v2 but showed weak positive correlation post-v2. Pearson correlations taken at each timepoint and individual sub-group.



**Extended Data Fig. 7 | Multivariable logistic regression model presenting odds ratio of anti-SARS-CoV-2 RBD non-responsiveness after two COVID-19 vaccine doses.** Forest plot depicting the outcome of a multivariable logistic regression model, presenting the odds ratio of non-response as measured by a

Roche anti-RBD Ig titre of <0.8 AU/mL. All individuals in group 1 and group 2 with post-V2 serological titre included, except L-Cirr, UC, and CD groups which had no non-responders and therefore were not included in analysis. N = 1821 in disease group and n = 225 matched healthy controls.





**Extended Data Fig. 8 | Correlation of Oxford Immunotec T-Spot SARS-CoV-2 spike peptide pools.** Exploratory scatter plot to show correlation between the ELISpot Spike 1 + 2 & Full Spike Assay measures, for all patients with both values available in the Deep Immunophenotyping Group. Presented on the log scale. Pearson's correlation.

Extended Data Table 1 | Summary of COVID-19 severity after COVID-19 vaccination split by serological response

SARS-CoV-2 infection (Whole OCTAVE cohort)																					
Follow-up period	Responder status	Infection status	SC	HM	AAV	IA	HD	HD on IS	K-Tr	L-Tr	L-AI	L-Cirr	CD	UC	IBD-U	Auto-HSCT	Allo-HSCT	CAR-T	OCTAVE		
Serology breakdown	<6months post-V2	No response	Not infected	0 (0%)	1 (50%)	1 (5%)	7 (28%)	7 (88%)	5 (83%)	128 (91%)	1 (5%)	1 (20%)	-	-	-	0 (0%)	0 (0%)	6 (46%)	0 (0%)	157 (62%)	
			Infected	1 (33%)	0 (0%)	1 (5%)	1 (4%)	0 (0%)	0 (0%)	9 (6%)	0 (0%)	0 (0%)	0 (0%)	-	-	-	0 (0%)	0 (0%)	2 (15%)	2 (50%)	16 (6%)
			UK/NA	2 (67%)	1 (50%)	19 (90%)	17 (68%)	1 (13%)	1 (17%)	3 (2%)	19 (95%)	4 (80%)	4 (80%)	-	-	-	1 (100%)	5 (100%)	5 (38%)	2 (50%)	80 (32%)
		Total#	3 (1%)	2 (1%)	21 (8%)	25 (10%)	8 (3%)	6 (2%)	140 (55%)	20 (8%)	5 (2%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0%)	5 (2%)	13 (5%)	4 (2%)	253
		Low response	Not infected	3 (19%)	5 (71%)	0 (0%)	72 (35%)	31 (91%)	6 (86%)	131 (95%)	1 (4%)	1 (5%)	1 (6%)	11 (19%)	4 (17%)	0 (0%)	2 (33%)	15 (48%)	0 (0%)	0 (0%)	283 (47%)
			Infected	1 (6%)	0 (0%)	0 (0%)	10 (5%)	1 (3%)	0 (0%)	5 (4%)	0 (0%)	2 (10%)	0 (0%)	2 (4%)	0 (0%)	0 (0%)	0 (0%)	5 (16%)	0 (0%)	0 (0%)	26 (4%)
	UK/NA		12 (75%)	2 (29%)	4 (100%)	125 (60%)	2 (6%)	1 (14%)	2 (1%)	26 (96%)	18 (86%)	16 (94%)	44 (77%)	20 (83%)	1 (100%)	4 (67%)	11 (35%)	1 (100%)	1 (100%)	289 (48%)	
	Total#	16 (3%)	7 (1%)	4 (1%)	207 (35%)	34 (6%)	7 (1%)	138 (23%)	27 (5%)	21 (4%)	17 (3%)	57 (10%)	24 (4%)	1 (0%)	6 (1%)	31 (5%)	1 (0%)	5 (2%)	598		
	High response	Not infected	60 (76%)	11 (61%)	3 (100%)	409 (89%)	147 (95%)	16 (94%)	172 (97%)	17 (50%)	32 (76%)	66 (65%)	55 (56%)	54 (67%)	2 (67%)	19 (90%)	30 (59%)	2 (100%)	10 (50%)	1095 (82%)	
		Infected	7 (9%)	1 (6%)	0 (0%)	25 (5%)	3 (2%)	0 (0%)	4 (2%)	3 (9%)	1 (2%)	5 (5%)	13 (13%)	5 (6%)	0 (0%)	1 (5%)	3 (6%)	0 (0%)	0 (0%)	71 (5%)	
		UK/NA	12 (15%)	6 (33%)	0 (0%)	23 (5%)	4 (3%)	1 (6%)	2 (1%)	14 (41%)	9 (21%)	30 (30%)	31 (31%)	22 (27%)	1 (33%)	1 (5%)	18 (35%)	0 (0%)	0 (0%)	174 (13%)	
	Total#	79 (6%)	18 (1%)	3 (0%)	457 (34%)	154 (11%)	17 (1%)	178 (13%)	34 (3%)	42 (3%)	101 (8%)	99 (7%)	81 (6%)	3 (0%)	21 (2%)	51 (4%)	2 (0%)	2 (0%)	1,340		
Overall	Not infected	63 (64%)	17 (63%)	4 (14%)	488 (71%)	185 (94%)	27 (90%)	431 (95%)	19 (23%)	34 (50%)	67 (57%)	66 (42%)	58 (55%)	2 (40%)	21 (66%)	51 (54%)	2 (29%)	2 (29%)	1535 (70%)		
	Infected	9 (9%)	1 (4%)	1 (4%)	36 (5%)	4 (2%)	0 (0%)	18 (4%)	3 (4%)	3 (4%)	5 (4%)	15 (10%)	5 (5%)	0 (0%)	1 (3%)	10 (11%)	2 (29%)	2 (29%)	113 (5%)		
	UK/NA	26 (27%)	9 (33%)	23 (82%)	165 (24%)	7 (4%)	3 (10%)	7 (2%)	59 (73%)	31 (46%)	46 (39%)	75 (48%)	42 (40%)	3 (60%)	10 (31%)	34 (36%)	3 (43%)	3 (43%)	543 (25%)		
Total#	98 (4%)	27 (1%)	28 (1%)	689 (31%)	196 (9%)	30 (1%)	456 (21%)	81 (4%)	68 (3%)	118 (5%)	156 (7%)	105 (5%)	5 (0%)	32 (1%)	95 (4%)	7 (0%)	2 (0%)	2,191			
6months post-V2 - 12months post-V1	No response	Not infected	1 (33%)	0 (0%)	1 (5%)	4 (16%)	4 (50%)	4 (67%)	93 (66%)	0 (0%)	0 (0%)	-	-	-	0 (0%)	0 (0%)	6 (46%)	1 (25%)	114 (45%)		
		Infected	0 (0%)	1 (50%)	2 (10%)	2 (8%)	3 (38%)	2 (33%)	37 (26%)	1 (5%)	1 (20%)	-	-	-	0 (0%)	0 (0%)	1 (8%)	0 (0%)	50 (20%)		
		UK/NA	2 (67%)	1 (50%)	18 (86%)	19 (76%)	1 (13%)	0 (0%)	10 (7%)	19 (95%)	4 (80%)	4 (80%)	-	-	-	1 (100%)	6 (46%)	3 (75%)	89 (35%)		
	Total#	3 (1%)	2 (1%)	21 (8%)	25 (10%)	8 (3%)	6 (2%)	140 (55%)	20 (8%)	5 (2%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (0%)	5 (2%)	13 (5%)	4 (2%)	253		
	Low response	Not infected	2 (13%)	4 (57%)	0 (0%)	69 (33%)	21 (62%)	5 (71%)	101 (73%)	0 (0%)	1 (5%)	1 (6%)	7 (12%)	2 (8%)	0 (0%)	2 (33%)	15 (48%)	0 (0%)	0 (0%)	230 (38%)	
		Infected	1 (6%)	1 (14%)	0 (0%)	6 (3%)	6 (18%)	1 (14%)	31 (22%)	1 (4%)	2 (10%)	0 (0%)	14 (25%)	3 (13%)	0 (0%)	0 (0%)	2 (6%)	1 (100%)	1 (100%)	69 (12%)	
UK/NA		13 (81%)	2 (29%)	4 (100%)	132 (64%)	7 (21%)	1 (14%)	6 (4%)	26 (96%)	18 (86%)	16 (94%)	36 (63%)	19 (79%)	1 (100%)	4 (67%)	14 (45%)	0 (0%)	0 (0%)	299 (50%)		
Total#	16 (3%)	7 (1%)	4 (1%)	207 (35%)	34 (6%)	7 (1%)	138 (23%)	27 (5%)	21 (4%)	17 (3%)	57 (10%)	24 (4%)	1 (0%)	6 (1%)	31 (5%)	1 (0%)	2 (0%)	598			
High response	Not infected	46 (58%)	11 (61%)	3 (100%)	392 (86%)	110 (71%)	9 (53%)	136 (76%)	12 (35%)	24 (57%)	53 (52%)	39 (39%)	28 (35%)	2 (67%)	20 (95%)	25 (49%)	2 (100%)	2 (100%)	912 (68%)		
	Infected	8 (10%)	0 (0%)	0 (0%)	35 (8%)	30 (19%)	6 (35%)	37 (21%)	9 (26%)	9 (21%)	27 (27%)	38 (38%)	35 (43%)	1 (33%)	1 (5%)	6 (12%)	0 (0%)	0 (0%)	242 (18%)		
	UK/NA	25 (32%)	7 (39%)	0 (0%)	30 (7%)	14 (9%)	2 (12%)	5 (3%)	13 (38%)	9 (21%)	21 (21%)	22 (22%)	18 (22%)	0 (0%)	0 (0%)	20 (39%)	0 (0%)	0 (0%)	186 (14%)		
Total#	79 (6%)	18 (1%)	3 (0%)	457 (34%)	154 (11%)	17 (1%)	178 (13%)	34 (3%)	42 (3%)	101 (8%)	99 (7%)	81 (6%)	3 (0%)	21 (2%)	51 (4%)	2 (0%)	2 (0%)	1,340			
Overall	Not infected	49 (50%)	15 (56%)	4 (14%)	465 (67%)	135 (69%)	18 (60%)	330 (72%)	12 (15%)	25 (33%)	54 (46%)	46 (29%)	30 (29%)	2 (40%)	22 (69%)	46 (48%)	3 (43%)	3 (43%)	1256 (57%)		
	Infected	9 (9%)	2 (7%)	2 (7%)	43 (6%)	39 (20%)	9 (30%)	105 (23%)	11 (14%)	12 (18%)	27 (23%)	52 (33%)	38 (36%)	1 (20%)	1 (3%)	9 (9%)	1 (14%)	1 (14%)	361 (16%)		
	UK/NA	40 (41%)	10 (37%)	22 (79%)	181 (26%)	22 (11%)	3 (10%)	21 (5%)	58 (72%)	31 (46%)	37 (31%)	58 (37%)	37 (35%)	2 (40%)	9 (28%)	40 (42%)	3 (43%)	3 (43%)	574 (26%)		
Total#	98 (4%)	27 (1%)	28 (1%)	689 (31%)	196 (9%)	30 (1%)	456 (21%)	81 (4%)	68 (3%)	118 (5%)	156 (7%)	105 (5%)	5 (0%)	32 (1%)	95 (4%)	7 (0%)	2 (0%)	2,191			
T cell Breakdown	<6months post-V2	No response	Not infected	4 (67%)	-	0 (0%)	2 (50%)	21 (95%)	4 (100%)	-	1 (17%)	1 (50%)	2 (100%)	-	1 (25%)	-	2 (100%)	6 (55%)	0 (0%)	44 (67%)	
			Infected	0 (0%)	-	0 (0%)	0 (0%)	0 (0%)	0 (0%)	-	0 (0%)	0 (0%)	0 (0%)	-	0 (0%)	-	0 (0%)	2 (18%)	0 (0%)	2 (3%)	
			UK/NA	2 (33%)	-	2 (100%)	2 (50%)	1 (5%)	0 (0%)	-	5 (83%)	1 (50%)	0 (0%)	-	3 (75%)	-	0 (0%)	3 (27%)	1 (100%)	20 (30%)	
	Total#	6 (9%)	0 (0%)	2 (3%)	4 (6%)	22 (33%)	4 (6%)	-	6 (9%)	2 (3%)	2 (3%)	0 (0%)	4 (6%)	-	2 (3%)	11 (17%)	1 (2%)	66			
	Yes response	Not infected	37 (65%)	13 (76%)	4 (15%)	47 (43%)	94 (94%)	8 (100%)	-	6 (33%)	13 (54%)	10 (42%)	22 (54%)	26 (63%)	-	8 (73%)	19 (70%)	2 (67%)	2 (67%)	309 (61%)	
		Infected	4 (7%)	1 (6%)	1 (4%)	8 (7%)	2 (2%)	0 (0%)	-	1 (6%)	0 (0%)	3 (13%)	1 (2%)	2 (5%)	-	0 (0%)	1 (4%)	0 (0%)	0 (0%)	24 (5%)	
UK/NA		16 (28%)	3 (18%)	21 (81%)	55 (50%)	4 (4%)	0 (0%)	-	11 (61%)	11 (46%)	11 (46%)	18 (44%)	13 (32%)	-	3 (27%)	7 (26%)	1 (33%)	1 (33%)	174 (34%)		
Total#	57 (11%)	17 (3%)	26 (5%)	110 (22%)	100 (20%)	8 (2%)	-	18 (4%)	24 (5%)	24 (5%)	41 (8%)	41 (8%)	-	11 (2%)	27 (5%)	3 (1%)	3 (1%)	507			
Overall	Not infected	41 (65%)	13 (76%)	4 (14%)	49 (43%)	115 (94%)	12 (100%)	-	7 (29%)	14 (54%)	12 (46%)	22 (54%)	27 (60%)	-	10 (77%)	25 (66%)	2 (50%)	2 (50%)	353 (62%)		
	Infected	4 (6%)	1 (6%)	1 (4%)	8 (7%)	2 (2%)	0 (0%)	-	1 (4%)	0 (0%)	3 (12%)	1 (2%)	2 (4%)	-	0 (0%)	3 (8%)	0 (0%)	0 (0%)	26 (5%)		
	UK/NA	18 (29%)	3 (18%)	23 (82%)	57 (50%)	5 (4%)	0 (0%)	-	16 (67%)	12 (46%)	11 (42%)	18 (44%)	16 (36%)	-	3 (23%)	10 (26%)	2 (50%)	2 (50%)	194 (34%)		
Total#	63 (11%)	17 (3%)	28 (5%)	114 (20%)	122 (21%)	12 (2%)	-	24 (4%)	26 (5%)	26 (5%)	41 (7%)	45 (8%)	-	13 (2%)	38 (7%)	4 (1%)	4 (1%)	573			
6months post-V2 - 12months post-V1	No response	Not infected	3 (50%)	-	0 (0%)	0 (0%)	12 (55%)	2 (50%)	-	0 (0%)	1 (50%)	2 (100%)	-	0 (0%)	-	2 (100%)	7 (64%)	0 (0%)	0 (0%)	29 (44%)	
		Infected	0 (0%)	-	0 (0%)	2 (50%)	8 (36%)	2 (50%)	-	1 (17%)	0 (0%)	0 (0%)	-	1 (25%)	-	0 (0%)	1 (9%)	0 (0%)	1 (100%)	16 (24%)	
		UK/NA	3 (50%)	-	2 (100%)	2 (50%)	2 (9%)	0 (0%)	-	5 (83%)	1 (50%)	0 (0%)	-	3 (75%)	-	0 (0%)	3 (27%)	0 (0%)	0 (0%)	21 (32%)	
	Total#	6 (9%)	0 (0%)	2 (3%)	4 (6%)	22 (33%)	4 (6%)	-	6 (9%)	2 (3%)	2 (3%)	0 (0%)	4 (6%)	-	2 (3%)	11 (17%)	1 (2%)	1 (2%)	66		
	Yes response	Not infected	30 (53%)	12 (71%)	4 (15%)	45 (41%)	76 (76%)	5 (63%)	-	5 (28%)	7 (29%)	8 (33%)	13 (32%)	14 (34%)	-	8 (73%)	17 (63%)	2 (67%)	2 (67%)	246 (49%)	
		Infected	4 (7%)	1 (6%)	2 (8%)	10 (9%)	11 (11%)	3 (38%)	-	2 (11%)	5 (21%)	4 (17%)	10 (24%)	14 (34%)	-	1 (9%)	1 (4%)	0 (0%)	0 (0%)	68 (13%)	
UK/NA		23 (40%)	4 (24%)	20 (77%)	55 (50%)	13 (13%)	0 (0%)	-	11 (61%)	12 (50%)	12 (50%)	18 (44%)	13 (32%)	-	2 (18%)	9 (33%)	1 (33%)	1 (33%)	193 (38%)		
Total#	57 (11%)	17 (3%)	26 (5%)	110 (22%)	100 (20%)	8 (2%)	-	18 (4%)	24 (5%)	24 (5%)	41 (8%)	41 (8%)	-	11 (2%)	27 (5%)	3 (1%)	3 (1%)	507			
Overall	Not infected	33 (52%)	12 (71%)	4 (14%)	45 (39%)	88 (72%)	7 (58%)	-	5 (21%)	8 (31%)	10 (38%)	13 (32%)	14 (31%)	-	10 (77%)	24 (63%)	2 (50%)	2 (50%)	275 (48%)		
	Infected	4 (6%)	1 (6%)	2 (7%)	12 (11%)	19 (16%)	5 (42%)	-	3 (13%)	5 (19%)	4 (15%)	10 (24%)	15 (33%)	-	1 (8%)	2 (5%)	1 (25%)	1 (25%)	84 (15%)		
	UK/NA	26 (41%)	4 (24%)	22 (79%)	57 (50%)	15 (12%)	0 (0%)	-	16 (67%)	13 (50%)	12 (46%)	18 (44%)	16 (36%)	-	2 (15%)	12 (32%)	1 (25%)	1 (25%)	214 (37%)		
Total#	63 (11%)	17 (3%)	28 (5%)	114 (20%)	122 (21%)	12 (2%)	-	24 (4%)	26 (5%)	26 (5%)	41 (7%)	45 (8%)	-	13 (2%)	38 (7%)	4 (1%)	4 (1%)	573			

Summary of COVID-19 severity reported in combined follow-up periods after COVID-19 vaccination for all immunocompromised patients in OCTAVE, split by disease subgroup and based on Roche anti-RBD Ig assay result  $\geq 0.8$  AU ml<sup>-1</sup>, low response  $< 380$  AU ml<sup>-1</sup> and high response  $> 380$  AU ml<sup>-1</sup> at

**Extended Data Table 2 | Summary of COVID-19 severity after COVID-19 vaccination split by T cell response**

		Anti-RBD Ig breakdown - <6months post-v2 - 12months post-V1 (n (%))																
		SC	HM	AAV	IA	HD	HD on IS	K-Tr	L-Tr	L-AI	L-Cirr	CD	UC	IBD-U	Auto-HSCT	Allo-HSCT	CAR-T	OCTAVE
No Response	Asymptomatic	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (50%)	5 (11%)	0 (0%)	0 (0%)	-	-	-	-	-	0 (0%)	0 (0%)	6 (9%)
	Symptomatic	1 (100%)	1 (100%)	2 (67%)	1 (33%)	2 (67%)	0 (0%)	25 (54%)	1 (100%)	1 (100%)	-	-	-	-	-	1 (33%)	0 (0%)	35 (53%)
	Hospitalised - No Oxygen Required	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	3 (7%)	0 (0%)	0 (0%)	-	-	-	-	-	0 (0%)	2 (100%)	5 (8%)
	Hospitalised - Oxygen Required	0 (0%)	0 (0%)	0 (0%)	1 (33%)	0 (0%)	0 (0%)	8 (17%)	0 (0%)	0 (0%)	-	-	-	-	-	0 (0%)	0 (0%)	9 (14%)
	ITU	0 (0%)	0 (0%)	0 (0%)	1 (33%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	-	-	-	-	-	0 (0%)	0 (0%)	1 (2%)
	COVID-19 related mortality	0 (0%)	0 (0%)	1 (33%)	0 (0%)	1 (33%)	1 (50%)	2 (4%)	0 (0%)	0 (0%)	-	-	-	-	-	0 (0%)	0 (0%)	5 (8%)
	Unknown/NA	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	3 (7%)	0 (0%)	0 (0%)	-	-	-	-	-	2 (67%)	0 (0%)	5 (8%)
	<b>Total#</b>	<b>1 (2%)</b>	<b>1 (2%)</b>	<b>3 (5%)</b>	<b>3 (5%)</b>	<b>3 (5%)</b>	<b>2 (3%)</b>	<b>46 (70%)</b>	<b>1 (2%)</b>	<b>1 (2%)</b>	<b>0 (0%)</b>	<b>0 (0%)</b>	<b>0 (0%)</b>	<b>0 (0%)</b>	<b>0 (0%)</b>	<b>3 (5%)</b>	<b>2 (3%)</b>	<b>66</b>
Low response	Asymptomatic	0 (0%)	0 (0%)	-	0 (0%)	2 (29%)	0 (0%)	5 (14%)	0 (0%)	0 (0%)	-	0 (0%)	0 (0%)	-	-	1 (14%)	0 (0%)	8 (8%)
	Symptomatic	1 (50%)	0 (0%)	-	13 (81%)	4 (57%)	0 (0%)	24 (67%)	1 (100%)	3 (75%)	-	15 (94%)	3 (100%)	-	-	4 (57%)	0 (0%)	68 (72%)
	Hospitalised - No Oxygen Required	0 (0%)	0 (0%)	-	1 (6%)	0 (0%)	0 (0%)	5 (14%)	0 (0%)	0 (0%)	-	0 (0%)	0 (0%)	-	-	0 (0%)	0 (0%)	6 (6%)
	Hospitalised - Oxygen Required	0 (0%)	0 (0%)	-	1 (6%)	1 (14%)	0 (0%)	1 (3%)	0 (0%)	0 (0%)	-	0 (0%)	0 (0%)	-	-	0 (0%)	0 (0%)	3 (3%)
	ITU	0 (0%)	0 (0%)	-	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	-	0 (0%)	0 (0%)	-	-	1 (14%)	0 (0%)	1 (1%)
	COVID-19 related mortality	0 (0%)	0 (0%)	-	0 (0%)	0 (0%)	1 (100%)	1 (3%)	0 (0%)	0 (0%)	-	0 (0%)	0 (0%)	-	-	0 (0%)	1 (100%)	3 (3%)
	Unknown/NA	1 (50%)	1 (100%)	-	1 (6%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (25%)	-	1 (6%)	0 (0%)	-	-	1 (14%)	0 (0%)	6 (6%)
	<b>Total#</b>	<b>2 (2%)</b>	<b>1 (1%)</b>	<b>0 (0%)</b>	<b>16 (17%)</b>	<b>7 (7%)</b>	<b>1 (1%)</b>	<b>36 (38%)</b>	<b>1 (1%)</b>	<b>4 (4%)</b>	<b>0 (0%)</b>	<b>16 (17%)</b>	<b>3 (3%)</b>	<b>0 (0%)</b>	<b>0 (0%)</b>	<b>7 (7%)</b>	<b>1 (1%)</b>	<b>95</b>
High response	Asymptomatic	0 (0%)	0 (0%)	-	5 (8%)	13 (39%)	0 (0%)	11 (27%)	1 (8%)	1 (10%)	1 (3%)	1 (2%)	0 (0%)	0 (0%)	0 (0%)	2 (22%)	-	35 (11%)
	Symptomatic	12 (80%)	0 (0%)	-	48 (80%)	17 (52%)	6 (100%)	25 (61%)	10 (83%)	9 (90%)	27 (84%)	45 (88%)	39 (98%)	1 (100%)	1 (50%)	5 (56%)	-	245 (78%)
	Hospitalised - No Oxygen Required	0 (0%)	0 (0%)	-	0 (0%)	2 (6%)	0 (0%)	2 (5%)	0 (0%)	0 (0%)	0 (0%)	1 (2%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	5 (2%)
	Hospitalised - Oxygen Required	0 (0%)	0 (0%)	-	0 (0%)	1 (3%)	0 (0%)	0 (0%)	1 (8%)	0 (0%)	1 (3%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	3 (1%)
	ITU	0 (0%)	0 (0%)	-	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)
	COVID-19 related mortality	0 (0%)	0 (0%)	-	0 (0%)	0 (0%)	0 (0%)	1 (2%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (50%)	0 (0%)	-	2 (1%)
	Unknown/NA	3 (20%)	1 (100%)	-	7 (12%)	0 (0%)	0 (0%)	2 (5%)	0 (0%)	0 (0%)	3 (9%)	4 (8%)	1 (3%)	0 (0%)	0 (0%)	2 (22%)	-	23 (7%)
	<b>Total#</b>	<b>15 (5%)</b>	<b>1 (0%)</b>	<b>0 (0%)</b>	<b>60 (19%)</b>	<b>33 (11%)</b>	<b>6 (2%)</b>	<b>41 (13%)</b>	<b>12 (4%)</b>	<b>10 (3%)</b>	<b>32 (10%)</b>	<b>51 (16%)</b>	<b>40 (13%)</b>	<b>1 (0%)</b>	<b>2 (1%)</b>	<b>9 (3%)</b>	<b>0 (0%)</b>	<b>313</b>
Total	Asymptomatic	0 (0%)	0 (0%)	0 (0%)	5 (6%)	15 (35%)	1 (11%)	21 (17%)	1 (7%)	1 (7%)	1 (3%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	3 (16%)	0 (0%)	49 (10%)
	Symptomatic	14 (78%)	1 (33%)	2 (67%)	62 (78%)	23 (53%)	6 (67%)	74 (60%)	12 (86%)	13 (87%)	27 (84%)	60 (90%)	42 (98%)	1 (100%)	1 (50%)	10 (53%)	0 (0%)	348 (73%)
	Hospitalised - No Oxygen Required	0 (0%)	0 (0%)	0 (0%)	1 (1%)	2 (5%)	0 (0%)	10 (8%)	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	2 (67%)	16 (3%)
	Hospitalised - Oxygen Required	0 (0%)	0 (0%)	0 (0%)	2 (3%)	2 (5%)	0 (0%)	9 (7%)	1 (7%)	0 (0%)	1 (3%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	15 (3%)
	ITU	0 (0%)	0 (0%)	0 (0%)	1 (1%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (5%)	0 (0%)	2 (0%)
	COVID-19 related mortality	0 (0%)	0 (0%)	1 (33%)	0 (0%)	1 (2%)	2 (22%)	4 (3%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	0 (0%)	1 (50%)	0 (0%)	1 (33%)	10 (2%)
	Unknown/NA	4 (22%)	2 (67%)	0 (0%)	8 (10%)	0 (0%)	0 (0%)	5 (4%)	0 (0%)	1 (7%)	3 (9%)	5 (7%)	1 (2%)	0 (0%)	0 (0%)	5 (26%)	0 (0%)	34 (7%)
	<b>Total#</b>	<b>18 (4%)</b>	<b>3 (1%)</b>	<b>3 (1%)</b>	<b>79 (17%)</b>	<b>43 (9%)</b>	<b>9 (2%)</b>	<b>123 (26%)</b>	<b>14 (3%)</b>	<b>15 (3%)</b>	<b>32 (7%)</b>	<b>67 (14%)</b>	<b>43 (9%)</b>	<b>1 (0%)</b>	<b>2 (0%)</b>	<b>19 (4%)</b>	<b>3 (1%)</b>	<b>474</b>

Summary of COVID-19 severity in reported SARS-CoV-2-infected individuals after vaccination in group1 of the OCTAVE cohort, split by disease subgroup and based on IFN $\gamma$  ELISpot response to SARS-CoV-2 spike at the post-V2 timepoint. No response=OSFC/10<sup>5</sup>; yes response>OSFC/10<sup>6</sup>. \* Kidney transplant and undefined inflammatory bowel disease groups were not included in group 1. # % of total OCTAVE infections.

## Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our [Editorial Policies](#) and the [Editorial Policy Checklist](#).

### Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

n/a Confirmed

- The exact sample size ( $n$ ) for each experimental group/condition, given as a discrete number and unit of measurement
- A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- The statistical test(s) used AND whether they are one- or two-sided  
*Only common tests should be described solely by name; describe more complex techniques in the Methods section.*
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g.  $F$ ,  $t$ ,  $r$ ) with confidence intervals, effect sizes, degrees of freedom and  $P$  value noted  
*Give  $P$  values as exact values whenever suitable.*
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g. Cohen's  $d$ , Pearson's  $r$ ), indicating how they were calculated

*Our web collection on [statistics for biologists](#) contains articles on many of the points above.*

### Software and code

Policy information about [availability of computer code](#)

Data collection

Data analysis

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio [guidelines for submitting code & software](#) for further information.

### Data

Policy information about [availability of data](#)

All manuscripts must include a [data availability statement](#). This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our [policy](#)

Participant data and the associated supporting documentation will be available within 6 months after the publication of this manuscript. Details of our data request process is available on the CRCTU website. Only scientifically sound proposals from appropriately qualified research groups will be considered for data sharing. The decision to release data will be made by the CRCTU Director's Committee, who will consider the scientific validity of the request, the qualifications and resources of the research group, the views of the Chief Investigator and the trial steering committee, consent arrangements, the practicality of anonymising the requested data



and contractual obligations. A data sharing agreement will cover the terms and conditions of the release of trial data and will include publication requirements, authorship and acknowledgements and obligations for the responsible use of data. An anonymised encrypted dataset will be transferred directly using a secure method and in accordance with the University of Birmingham's IT guidance on encryption of data sets. Information on data requests, including a contact address and expected time frame of requests can be found at the following link: <https://www.birmingham.ac.uk/research/crcu/data-sharing-policy.aspx>

## Human research participants

Policy information about [studies involving human research participants and Sex and Gender in Research](#).

Reporting on sex and gender	Participants of male and female sex were included in this study and their demographics are included in Table 1. Sex was included as a variable in multivariable logistic models.
Population characteristics	The covariate-relevant population characteristics collected in all participants are included in Table 1 and include: Age, sex, ethnicity, BMI, Smoking status, diabetes diagnosis and disease phenotype.
Recruitment	<p>Written informed consent was obtained from all the participants. Adult patients in clinically vulnerable groups were recruited between 19 February 2021 and 01 October 2021 based on the following eligibility criteria:</p> <ul style="list-style-type: none"> <li>- Are eligible for vaccination by one of the SARS-CoV-2 vaccines approved by the MHRA administered in accordance with national guidelines.</li> <li>- Have not received their second dose of the vaccine for the "deep immunophenotyping group", or have not passed the day 28 post second vaccine dose timepoint (21-84 days after second vaccination) for the "serology group".</li> <li>- Have an anticipated life span of 6 months or greater.</li> <li>- Have a diagnosis belonging to one of the following disease groups: Solid cancer (SC); Haematological malignancy (HM); Rheumatic Inflammatory Conditions (including ANCA Associated Vasculitis on rituximab (AAV) and Inflammatory Arthritis (IA)), Chronic renal disease (including end-stage kidney disease and kidney transplantation (K-Tr)), Chronic liver disease (including liver cirrhosis (L-Cir), liver disease on immunosuppressive therapy (L-AI) or liver transplantation (L-Tr)), Inflammatory Bowel Disease on immunosuppressive therapy (IBD; Crohn's disease (CD), ulcerative colitis (UC) and undefined IBD-U) and Haematopoietic stem cell transplant patients (HSCT) (including patients that were previously treated with CAR-T therapies, however none with CAR-T monotherapy).</li> </ul> <p>Investigators chose whether to recruit adult participants into a "serology group" for the evaluation of SARS-CoV-2 spike Ab responses 28 days after V2 or a "deep immune phenotyping group" for the evaluation of T cell and humoral responses.</p> <p>Participants were recruited as per the above recruitment criteria and as listed in the study protocol (supplementary).</p>
Ethics oversight	It was approved by the UK Medicines and Healthcare Products Regulatory Agency on the 5th February 2021 and the London and Chelsea Research Ethics Committee (REC Ref:21/HRA/0489) on 12th February 2021. The protocol has subsequently been amended eight times with five substantial amendments (with ethical approvals dated 3rd March 2021, 19th April 2021, 24th December 2021, and 4th April 2022) and three non-substantial amendments protocol version dated 22nd April 2021, 14th July 2021, and 10th September 2021).

Note that full information on the approval of the study protocol must also be provided in the manuscript.

## Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

Life sciences       Behavioural & social sciences       Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see [nature.com/documents/nr-reporting-summary-flat.pdf](https://www.nature.com/documents/nr-reporting-summary-flat.pdf)

## Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size	The sample size was based on the numbers of recruits that were estimated to have been able to recruit within the short space of time required. An effect size calculation, based on a t-test was done to provide information as to whether the number of recruits would be sufficient
Data exclusions	Missing data were excluded from the analyses. No other data were omitted.
Replication	Analyses were independently reproduced by a separate statistician where appropriate (replicated one time). Results were compared and no discrepancies were found. For Roche anti-SARS-CoV-2 S Elecsys assays performed at UKHSA, and T-SPOT assays performed at Oxford Immunotec samples were tested in singlets, in highly standardized and reproducible assays. For ELISpot assays done to assess variant of concern cross-reactivity, they were run in duplicate.
Randomization	This was an observational study and as such randomization was not required. Patients were selected based on inclusion criteria above, and therefore were not randomized.

## Blinding

Blinding was not required for this study as recruits were receiving whichever COVID-19 vaccine as available as part of the UK COVID-19 vaccine roll-out. However, as recruitment was being carried out at numerous different sites, results relating to patient responses to the vaccine were not shared until after the adult cohort recruitment had been closed.

## Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.

### Materials & experimental systems

n/a	Involved in the study
<input type="checkbox"/>	<input checked="" type="checkbox"/> Antibodies
<input checked="" type="checkbox"/>	<input type="checkbox"/> Eukaryotic cell lines
<input checked="" type="checkbox"/>	<input type="checkbox"/> Palaeontology and archaeology
<input checked="" type="checkbox"/>	<input type="checkbox"/> Animals and other organisms
<input type="checkbox"/>	<input checked="" type="checkbox"/> Clinical data
<input checked="" type="checkbox"/>	<input type="checkbox"/> Dual use research of concern

### Methods

n/a	Involved in the study
<input checked="" type="checkbox"/>	<input type="checkbox"/> ChIP-seq
<input checked="" type="checkbox"/>	<input type="checkbox"/> Flow cytometry
<input checked="" type="checkbox"/>	<input type="checkbox"/> MRI-based neuroimaging

## Antibodies

Antibodies used	anti-human IFN $\gamma$ monoclonal antibody (mAb), clone 1-D1K, Mabtech, cat 3420-2A ; anti-human IFN $\gamma$ biotinylated detection antibody (clone 7-B6-1) Mabtech, cat 3420-2A. Goat anti-human IgG, HRP conjugate, Sigma, UK cat AP112P.
Validation	IFN $\gamma$ mAb reference: Cecil Czerkinsky, Gudrun Andersson, Hans-Peter Ekre, Lars-Åke Nilsson, Lars Klareskog, Örjan Ouchterlony, Reverse ELISPOT assay for clonal analysis of cytokine production I. Enumeration of gamma-interferon-secreting cells, Journal of Immunological Methods, Volume 110, Issue 1, 1988

## Clinical data

Policy information about [clinical studies](#)

All manuscripts should comply with the ICMJE [guidelines for publication of clinical research](#) and a completed [CONSORT checklist](#) must be included with all submissions.

Clinical trial registration	ISRCTN12821688
Study protocol	Study protocol included in manuscript supplementary/appendix.
Data collection	Data were collected and stored using a REDCap v12.3.1 ©2022 Vanderbilt University. Recruitment and data occurred between 19 February 2021 and 01 October 2021
Outcomes	<p><b>Primary Outcomes</b> Vaccine Specific Immunogenicity:</p> <ol style="list-style-type: none"> <li>1) To measure the presence and amount of serum antibodies to discriminate IgG responses to SARS-CoV-2 from vaccination and/or infection.</li> <li>2) To measure T cell responses to SARS-CoV-2 peptides following vaccination.</li> </ol> <p><b>Measurement:</b></p> <ol style="list-style-type: none"> <li>1) Anti-SARS-CoV-2 IgG Abs following vaccination will be measured using the Roche platforms by the UK Health Security Agency formerly known as Public Health England Laboratories at Porton Down. The Roche assay measures the presence and amount of serum antibodies to both the spike (S) and the nucleocapsid (N) antigens of SARS-CoV-2. This assay will enable the discrimination of IgG responses to SARS-CoV-2 that results from vaccination and/or SARS-CoV-2 infection.</li> <li>2) T cell responses to SARS-CoV-2 peptides following vaccination will be measured using the Oxford Immunotec modified T-SPOT Discovery SARS-CoV-2 assay. This IFN<math>\gamma</math> ELISpot assay will provide insights into the participants' reactivity to SARS-CoV-2 S1, S2, N and membrane peptides.</li> </ol> <p><b>Secondary Outcomes</b> Clinical Protection: The first symptomatic PCR-proven COVID-19 occurrence from 14 days after first dose of vaccine in participants without evidence of prior infection with SARS-CoV-2.</p> <p><b>Measurement:</b> Incidence of first symptomatic, PCR-proven COVID-19 occurrence from 14 days after first dose of SARSCoV-2 vaccine in participants without evidence of prior infection with SARS-CoV-2 will be recorded and indications for protection against SARS-CoV-2 infection assessed.</p>